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ABSTRACT OF DISSERTATION

IDENTIFICATION AND CHARACTERIZATION OF EPITOPE SPECIFIC
IMMUNE RESPONSES IN HUMANS AND MICE
Cardiovascular disease (CVD) is a major cause of morbidity and mortality
around the world causing approximately 14% of total disease burden. A major
factor in the progression to major CVD within patients is immune activation, which
led to the study of various immune products as potential biomarkers for the
prediction of cardiovascular events, including antigen-specific antibodies and
immune complexes. One focus of this biomarker research is IgG autoantibodies
targeting apolipoprotein A-I (ApoA-I), and several studies of these antibodies have
found an association with increased CVD events. Based on the encouraging
results from these studies and previous research which has identified the presence
of ApoA-I/IgG immune complexes in humans and mice, we hypothesized that
ApoA-I/IgG immune complexes may serve as a biomarker for cardiovascular
disease risk in patients.
To study the potential association between ApoA-I/IgG immune complexes
and CVD events, an immunoassay was designed to detect immune complexes by
utilizing a capture antibody specific for ApoA-I and a detection antibody specific for
human IgG. ELISA were completed in samples from 359 patients with a history of
coronary artery disease who were followed for a median of 4.1 years. Responses
in this assay are independently associated with CVD events after adjustment for 8
common CVD risk factors with an adjusted hazard ratio of 1.90 (95% CI, 1.03–
3.49; p=0.038) when comparing subjects in the lowest tertile ELISA values to
subjects in the highest tertile.
Additional studies using samples from a cohort of blood donors sought to
measure immune complexes containing a related protein, apolipoprotein B-100
(ApoB-100), by changing the capture antibody in the assay. The detected
absorbance values are similar when utilizing a goat anti-ApoA-I IgG capture
antibody or a goat anti-ApoB-100 IgG capture antibody, a possible indication of
interference in our assay. Further studies find that the absorbance values in this
ELISA depend on capture antibody species of origin and not the specificity of the
antibody. Analyte identification occurs via the completion of competition ELISAs
and plasma fractionation studies which indicate that the immunoassay results are

caused by a human IgG antibody binding to goat-IgG. Characterization of these
antibodies indicate that they bind with a high affinity to the heavy chain of goat IgG.
Taken together, these results indicate that human anti-goat antibodies may serve
as a biomarker for CVD events in patients.
Additional studies presented in this dissertation include development of high
throughput ELISA methodology and modulation of epitope-specific immune
responses via liposomal injections.
KEYWORDS: Cardiovascular Disease, Immunoglobulin G, Antibodies, Human
anti-Animal Antibodies
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CHAPTER 1. INTRODUCTION
The focus of this dissertation will be on the identification and characterization
of a novel biomarker for cardiovascular disease (CVD) in patients. In this
introduction, I will first explore the extreme morbidity and mortality of CVD in
patients, as well as the nature of lipoproteins, both as cardiovascular risk factors
and contributing agents to the development of an atherosclerotic plaque.
Subsequently, I will describe the connections between immune system activation
and the development of CVD, evaluating both clinical correlations and studies in
animal models. Based on the role of the immune system in CVD, I will then assess
the literature on the use of antigen-specific antibodies in CVD risk prediction. At
this point I will shift in focus and introduce a form of clinical assay interferent, antianimal antibodies, and describe the consequences of these antibodies in clinical
assays. These sections frame the discussion of the major data presented in this
dissertation, focusing on the discovery of a novel antibody-based biomarker for
CVD progression in patients and then the identification and characterization of this
biomarker as a form of human anti-animal antibodies, specifically human IgG antigoat IgG.
1.1

Cardiovascular disease

CVD is a major cause of death and disability globally and is largely caused
by the formation of plaques in the arterial walls. These plaques develop over time
and are correlated with the amount of cholesterol within the blood, particularly
cholesterol within specific lipoprotein particles, including low-density lipoprotein
(LDL), intermediate density lipoprotein (IDL), and chylomicrons. Additional risk
factors beyond lipids have also been identified, leading to a need for a systemic
approach to CVD risk prediction in patients. This section will provide a broad
overview of the impact of CVD and the role of lipids in its development.
CVD is a broad group of conditions responsible for significant morbidity and
mortality around the world. These diseases include ischemic disease, where blood
flow to specific tissues is limited or fully obstructed; congenital heart disease,
where there is abnormal or incomplete development of cardiovascular tissue;
arrhythmic disorders, where electrical conductivity in the heart leads to aberrant
cardiac function; and heart failure, where the heart is unable to provide sufficient
blood to supply the body.1, 2 In the United States specifically, the National Health
and Nutrition Examination Survey indicated that 49.2% of Americans over 20 years
old have a form of CVD and the National Heart Lung and Blood Institute estimated
that CVD has a total annual cost of $363.4 billion.1 Internationally, a Global Burden
of Disease study determined that CVD had one of the largest negative impact on
human health of any disease, accounting for 15% of all disability associated life
year lost.3 Further, CVD is noted to be the largest single cause of death with an
estimated 17.9 million deaths due to CVD in 2016.1
1

A major driver of many forms of CVD in patients is the presence and growth
of atherosclerotic plaques in the artery walls. As these plaques grow, they may
begin to occlude the flow of blood through the arteries, causing tissue ischemia.
This is a major cause of specific forms of CVD including stable angina pectoris, if
the occlusion effects coronary vessels, and peripheral arterial disease, if the
occlusion effects the limbs.4, 5 As plaques enlarge they can also become unstable
and prone to rupture.4, 6 When rupture occurs, a necrotic cell core is exposed to
blood leading to the activation of clotting factors and rapid development of a clot
that can induce acute ischemia.4, 6 These events are major causes of death
internationally with over 8 million deaths due to ischemic heart disease and 3
million deaths due to ischemic stroke in 2013.4, 7 Because of the contribution of the
plaques to CVD in patients, they are the target of extensive research.
A result of this research focus was identification of cholesterol within low
density lipoprotein (LDL) particles as a major risk factor for CVD events. In the
early 1900s, scientists first determined that atherosclerotic plaques were enriched
with cholesterol, followed by the discovery that high cholesterol diets increased
atherosclerosis in rabbits.8 Further work in this field has shown that patients with
elevated levels of blood cholesterol are at increased risk for the development of
CVD.9, 10 The role of cholesterol within a specific particle, known as LDL, is
highlighted in patients and mice with a genetic deficiency of the LDL receptor.11, 12
This deficiency leads to elevated LDL cholesterol levels (LDL-C), early
atherosclerotic plaque development, and results in early CVD events in patients.
11, 12
Based on the correlations between CVD and LDL-C, pharmaceutical
interventions have been developed to lower LDL-C and therefore lower CVD risk.
LDL-C lowering therapeutics include the statins, a drug class which blocks the
cholesterol biosynthetic pathway and is strongly associated with decreased CVD
events in patients. In patients with elevated LDL-C despite statin therapy an
alternative therapeutic strategy is inhibition of the natural enzyme Proprotein
Convertase Subtillisin/Kexin type 9 (PCSK9) which leads to degradation of the LDL
receptor. Treatment with these PCSK9 inhibitors leads to reductions in LDL-C and
reduction in CVD disease events in patients.13, 14 The combination of clinical
correlations and pharmacological data clearly indicate the role of elevated
cholesterol levels, specifically LDL-C, in the development of atherosclerosis.
While native LDL is commonly found in circulation, much of the LDL within
an atherosclerotic plaque is oxidized. Analysis of atherosclerotic plaques indicates
the presence of both oxidized phospholipids and oxidized apolipoprotein B-100
(ApoB-100), the major protein of LDL, within atherosclerotic plaques.15-19 Although
the exact mechanism of this oxidation within the plaque has yet to be fully
elucidated, a combination of in vitro, in vivo, and ex vivo studies indicate a potential
role for both enzymatic oxidation via enzymes such as myeloperoxidase (MPO)
and inducible NO synthase (iNOS) as well as a potential role for metal ions and
Nitric Oxide (NO) in the generation of oxidized LDL (oxLDL).20-22 Irrespective of the
2

exact mechanism, the formation of oxLDL appears to be a critical event in the
pathogenesis of atherosclerosis. OxLDL has been shown to induce endothelial cell
activation, which leads to increased expression of adhesion molecules promoting
entry of immune cells into the plaque. OxLDL also induces inflammation and lipid
loading of macrophages.23-28 These immune mechanisms will be further discussed
in 1.3 focusing on immune cells.
High density lipoprotein (HDL) is an additional lipid carrying particle which
has been observed to counteract some of the pro-atherosclerotic properties of LDL
and oxLDL. HDL cholesterol levels (HDL-C) were originally determined to correlate
with deceased CVD progression in the Framingham study.29 Pharmacological
therapies have subsequently been developed with the purpose of increasing HDLC to reduce CVD events. These therapeutic agents have successfully raised HDLC; however, the effect on cardiovascular health and total mortality has been
minimal.30 Despite the failure of HDL-C elevating therapeutics, evaluations of HDL
indicate that the particles have atheroprotective properties. In vitro experiments
indicate that HDL and specific HDL subfractions promote the efflux of cholesterol
from several cell types, including LDL-loaded macrophages and further, that the
relative ability of plasma HDL to efflux cholesterol was an independent predictor of
CVD outcomes in patients.31-34 In vivo, cholesterol efflux is the initial step of reverse
cholesterol transport (RCT), the migration of peripheral cholesterol to the liver for
excretion. RCT was increased in an animal model with overexpression of the major
protein of HDL, apolipoprotein A-I (ApoA-I), highlighting the contribution of HDL to
the process.35 The atheroprotective effects of HDL extend beyond RCT, as HDL
and ApoA-I inhibit activation of both endothelial cells and monocytes, causing
decreased expression of adhesion molecules, and potentially decreased
production of oxLDL.36-40 The role of HDL and ApoA-I in opposition to LDL and
oxLDL supports the observation that HDL-C is associated with decreased CVD,
even though HDL-C raising therapeutics have failed clinically.
Cholesterol levels are strong predictors of CVD, but researchers have
determined that additional demographic and clinical factors help predict CVD. This
led to the development of risk calculators employing these additional factors to
evaluate individual patients. The Framingham calculator includes the patient’s
gender, age, systolic blood pressure, total cholesterol, and HDL-C in addition to
patient status determination of blood pressure medication status, smoking status,
and diabetes diagnosis.41 A related calculation developed by the American College
of Cardiology and the American Heart Association utilizes the same risk factors as
the Framingham calculator but with modified equations based on the patient’s
race.42 These calculators demonstrate important risk factors beyond lipid levels in
CVD development; however, even these multifactorial calculators have limitations
and additional factors capable of improving prediction are needed.

3

1.2

The role of inflammation in CVD

Inflammation is a major driver of the development of CVD both in animal
models and in patients. Clinical correlations provide an initial connection between
inflammation and CVD and are complemented by animal studies which show that
decreasing inflammation via genetic or pharmaceutical intervention reduces the
development of atherosclerosis. Several clinical trials have been completed to
evaluate the effects of immunomodulation on CVD development, including a trial
where a monoclonal antibody suppressed CVD events. This section will elaborate
on the role of inflammation in CVD as observed in patients and in animal models.
Observational studies in patients connect inflammation with CVD risk.
Multiple prospective studies of the inflammatory marker C-reactive protein find
association between this marker and CVD events.43-46 In genetic analyses,
mendelian randomization studies identify polymorphisms which impact
inflammatory signaling are also associated with CVD events.47, 48 Further, patients
with autoimmune diseases, and the associated chronic inflammation, are at an
increased risk for early CVD development.49 These associations prompt evaluation
of the effect of inflammation in animal models.
Manipulations in animal models directly connect inflammation and
atherosclerosis development. While wild type (WT) mice are largely resistant to
the development of atherosclerosis, genetic models have been developed to
induce atherosclerosis via the deficiency of the genes for either apolipoprotein E
(Apoe) or the LDL receptor (Ldlr).12, 50, 51 These atherogenic models are used in
the context of inflammatory pathway manipulation and the effect of the
manipulation is determined by comparing atherosclerosis in experimental and
control animals. Manipulation of key mediators of inflammation including cytokines
and costimulatory molecules in atheroprone mice provides a platform to evaluate
the effect of specific signaling cascades in atherosclerosis progression.52 To this
end over expression of interleukin-10 (IL-10), an anti-inflammatory signaling
molecule, has been shown to reduce the development of atherosclerosis in several
experiments.53-55 While many studies are based on systemic changes in cytokine
signaling, Zhang et al. grafted carotid artery section from mice with a genetic
deficiency of the receptor for an inflammatory cytokine, tumor necrosis factor
(TNF), into the carotid artery of Apoe-/- mice. In this study mice receiving Tnfr1-/arteries had a decreased plaque area compared to control mice, an indication of
the atherogenic effects of cytokine signaling within the artery itself.56 Beyond the
genetic models, anti-inflammatory pharmaceutical intervention have also been
evaluated. Mach et al. investigated the effect of decreasing inflammation in Ldlr-/by utilizing a monoclonal antibody targeting CD40L.57 CD40L is a cell surface costimulatory protein that interacts with CD40 to activate adaptive immune cells such
as B cells and T cells, which require additional stimuli in addition to their antigenspecific receptor to initiate full effector functions.58 Anti-CD40 antibody treatment
4

led to a 59% reduction in atherosclerotic plaque size in treated mice.57 In addition
to these mouse studies, work by Bulgarelli and colleagues also indicates a role for
inflammation in atherosclerosis in a rabbit model.59 In their report they administer
methotrexate, a small molecule therapeutic with anti-inflammatory effects, and find
reduction in plaque size.59 Modulation of inflammation in these animal models
clearly indicates the importance of inflammation in the development of
atherosclerosis.
Evidence of the role of the inflammatory immune response in mice led to
multiple randomized control trials of anti-inflammatory agents in patients. While
many of these therapeutics failed in clinical trials, colchicine and canakinumab, a
monoclonal antibody targeting the inflammatory cytokine IL-1β, decreased CVD
events in patients.60-65 Canakinumab is of particular interest because as a
monoclonal antibody it has a direct effect on inflammatory signaling via IL-1β, in
contrast the potential off-target effects of small molecular therapeutics complicates
interpretation, therefore, the results of the Canakinumab trial can be analyzed
focusing solely on inflammation. This trial enrolled patients with a history of a
myocardial infarction (MI) with elevated CRP at enrollment and randomized them
to receive canakinumab at one of three dosage or a placebo. Treatment with the
middle dosage of 150 mg per dose resulted in decreased CRP levels and
decreased cardiovascular events with a hazard ratio (HR) of 0.85 when compared
to placebo.65 Despite this improvement in cardiovascular outcomes, treatment with
canakinumab has limited clinical applicability in CVD due to an increased risk of
fatal infection and a lack of improvement in total mortality.65 The reduction of
cardiovascular events with total immunosuppression highlights the importance of
the immune system in CVD; however, due to the increase in infections, it is
important to determine the role of specific immune system components.
1.3

Immune cells in CVD

To fully appreciate the complexity of the immune system’s contribution to
CVD development it is necessary to evaluate the various immune cells and their
role in CVD. The innate immune response is largely driven by the activation of
Pattern Recognition Receptors (PRR) such as Toll-Like Receptors (TLR) or Lectinlike oxidized low-density lipoprotein receptor-1 (LOX-1). These receptors are
generally directed to patterns related to pathogens such as lipid-polysaccharide
recognized by TLR4. Beyond this however, the PRR can also bind to oxidized selfproteins, including ox-LDL binding to the LOX-1 receptor, leading to cellular
activation and inflammation. Many cells including endothelial cells, monocytes,
and macrophages contribute to the innate immune response by recognizing oxLDL
in the plaque. A complementary group of immune cells form the adaptive immune
system and contribute to the development of atherosclerosis as well. The adaptive
immune system relies on B and T cells possessing a unique cellular receptor which
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responds to a single target. This section will evaluate the specific contributions of
immune cells in CVD, including antigen-specific response by lymphocytes.
While not classically considered immune cells, endothelial cells participate in
the inflammatory response during atherogenesis. Atherosclerosis develops
primarily in regions where laminar flow is disrupted leading to turbulent flow, such
as branch points and curvatures, and analysis of the endothelial cells in these
areas of disrupted or turbulent flow indicates an enhanced inflammatory response
driven by Nf-κB.66, 67 Further, endothelial cells express the LOX-1 receptor which
binds oxLDL leading to increased expression of cellular adhesion proteins, the
cytokine TNF-α and both CD40 and CD40L, all potentially increase the local
inflammatory response and increase the infiltration of immune cells into the
plaque.23-28, 68
The activation of endothelial cells and expression of chemokines and
adhesion molecules attracts monocytes and allows for their entry into
atherosclerotic plaques. Prospective analysis in general population studies
indicate that the amount of both total monocytes and specific CD14++CD16monocytes are independent predictors of CVD events, an indication of the
importance of monocytes in CVD.69, 70 Complementary studies in mice find
enrichment of inflammatory monocytes, characterized as Ly-6hi, in the blood and
the aortas of atheroprone Apoe-/- mice on a western diet.71 Entry of monocytes into
plaques due to chemokine expression and increased adhesion molecules is a vital
step in atherosclerosis development as in vitro analysis indicates that monocytes
release inflammatory cytokines in response to oxLDL and in vivo evidence finds
that monocytes differentiate into macrophages within a plaque.72, 73
Progression of monocytes to macrophages produces cells which promote
atherogenesis. A potential contribution of macrophages to local inflammation
within the plaque is demonstrated in vitro where exposure to oxLDL induces the
expression of inflammatory cytokines.73, 74 Related ex vivo of analysis of
atherosclerotic plaques indicates that macrophages in plaque regions vulnerable
to rupture exhibit extracellular makers of inflammation, while macrophages in less
vulnerable regions exhibit a more anti-inflammatory phenotype.75, 76 Beyond
inflammation, macrophages have historically been appreciated for their
contribution to the plaque as lipid-laden foam cells.77, 78 While not all foam cells
arise from macrophage progenitors, internalization of excess cholesterol in oxLDL
particles potentially induces differentiation of macrophages into foam cells.77-80
Importantly, these macrophage-derived foam cells may contribute to the
development of the necrotic core within the plaque as oxLDL can induce apoptosis
in macrophages in vitro and analysis of plaques indicates that the necrotic core
contains significant levels the macrophage marker CD68 and that many foam cells
expressing CD68 are apoptotic in the region near the core.81-86

6

Evaluation of non-specific adaptive immune cells indicates that T and B cells
impact the development of atherosclerosis. Direct association of T and B cells with
atherosclerosis is demonstrated as Lldr-/- mice lacking these cells due to Rag1
deficiency have delayed atherosclerosis development.87 Alternatively, adaptive
cells can be connected to protection from CVD as Caligiuri and colleagues find
that transferring splenic B cells from older atherosclerotic Apoe-/- mice into younger
pre-atherosclerotic Apoe-/- mice reduced the development of atherosclerosis in the
recipient mice.88 Further analysis of T cell populations indicate while depletion of
total T helper cells leads to a reduction of atherosclerosis in mice, the individual TH
subsets may have distinct effects.89-91 A potential role for the relatively
inflammatory TH1 cells can be observed as transgenic mice lacking the TH1
transcriptional factor T-bet develop decreased atherosclerosis.92 In contrast, the
relatively immunosuppressive Treg cells are associated with atheroprotection as
atherosclerosis is increased in mice treated with an antibody that selectively
reduce the level of Treg cells.93 These results indicate the complicated role of
adaptive immune cells in the development of atherosclerosis; however, these
experiments do not explore a critical factor of T cell and B cell function, the epitopespecific receptor. These cells express a set of highly specific receptors, either the
T cell receptor or the B cell receptor, which are unique to individual naïve cells and
which binds to a specific target.94-96 It is this binding, in combination with
costimulatory proteins, such as CD40/CD40L, which fully activates the cell.58, 94, 95
Once activated TH cells release signaling molecules which directs additional
immune system function while B cells may produce antibodies, a secreted form of
the B cell receptor.94, 95 Given this critical function of epitope-specific receptors,
evaluations of the impact of T and B cells on atherosclerosis must consider
reactivity to specific antigens to fully understand the role of these cells.
Modulation of antigen-specific adaptive immune cells indicates the role of
these cells in atherosclerosis development. The impact of antigen-specific immune
cells can be appreciated in immunization models where induction of these cell
populations can lead to alterations of atherosclerosis. A common target of such
studies is the induction of antigen-specific B cells targeting oxLDL which is
measured by the presence of anti-oxLDL antibodies in the mice. Many studies find
that induction of these antibodies via immunization with oxLDL, or an alternative
antigen which leads to an anti-oxLDL antibody response, reduces the development
of atherosclerosis in mouse models.97-99 Gisterå and colleagues evaluated the
effect of antigen-specific T cells by creating transgenic T cells with receptors for
ApoB-100 peptides.100 Study of these cells in LDLr-/- mice expressing human
ApoB-100 found that two of the three transgenic T cells significantly reduced the
development of atherosclerosis, with a similar trend present with the final
transgenic T cell. Interestingly, these T cells induced an anti-oxLDL antibody
response, indicating the synergy between the adaptive immune cells as
simultaneous activation of T and B cells towards a target can lead to enhanced
activation. Shaw et al. indicate an alternative role of antigen-specific T cells. They
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immunize mice with a peptide from mouse ApoB-100 and observe that the induced
antigen-specific T cells led to increased atherosclerosis in an adaptive transfer
model utilizing Apoe-/- mice.101 The contrasting effect of T cells in these studies
highlights the importance of evaluation of the specific antigens targeted by
adaptive immune cells, and given their similar antigens, even a more specific
evaluation of the individual epitope targeted in an adaptive immune response.
1.4

Antigen-specific antibodies as biomarkers for CVD

Antigen-specific antibodies, a product of B cells, are frequently evaluated
for their ability to predict CVD in patients. Antibodies present in blood can be readily
measured based on antigen-specificity and antibody class. This enables the
comparison of the rate of CVD events to the level of antibodies targeting antigens
believed to impact the development of CVD, such as oxLDL, in large populations
of patients. This section will discuss the literature on antigen-specific antibodies as
biomarkers for CVD, including discussion of immune complexes formed between
antibodies and a specific antigen.
Studies of antigen-specific antibodies via ELISA is supported by the
modular design of the assay in which reagents may be exchanged to detect distinct
antibody responses of interest. In these assays, a target antigen of interest is
coated onto the plate which is then incubated with clinical samples allowing patient
antibodies to bind. The bound antibodies are then detected via a secondary
antibody specific for human immunoglobulin. This modular approach allows
exchange of the coating antigen leading to detection of antibodies with distinct
targets while exchange of the secondary antibody allows quantification of specific
classes of immunoglobulin which contribute to the antibody response.
Human IgG classes differ in development and function. The classes of
human immunoglobulin include IgM, IgG, IgE IgA and IgD, the distribution of these
antibodies are provided in Table 1-1. IgM is the initial antibody induced early in the
immune response and binds with low affinity; IgG is expressed later in the immune
response, after affinity maturation, and is the major immunoglobulin in circulation;
similarly IgA develops later in the immune response timeline and is the major
immunoglobulin of the mucosal immune response; IgE antibodies develop late in
the immune process and are active mediators of the allergic response; and IgD
antibodies are expressed along with IgM on naïve B cells, are only present in blood
at a low concentration and lack known antibody effector function.102 IgG and IgM
are the most common antibody classes in blood and generally contribute to
inflammation. 102 they also are the antibody classes most commonly measured as
antigen-specific antibodies in CVD research with IgA included in some studies,
particularly when investigating a target related to a mucosal pathogen.
A major antibody target studied in these experiments is oxLDL. Evaluation
of anti-oxLDL antibodies have returned inconsistent results as discussed in a
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systematic review by van den Burg and colleagues.103 Focusing on research in
patients without a history of CVD, studies of anti-oxLDL IgG have shown that this
potential biomarker indicates an increased risk of CVD events,104, 105 a decreased
risk of CVD events,106 or has no relationship with CVD events,107-110 Studies of
anti-oxLDL IgM in similar patient populations also show mixed results with some
studies indicating decreased risk in patients with elevated antibodies while other
studies found no correlation with disease.104-106, 108, 109 Importantly, some studies
in patients found a positive correlation between anti-oxLDL antibodies and CVD
risk which contrasts the results of mouse immunization experiments which often
find that induction of anti-oxLDL antibodies via immunization is associated with
decreased atherosclerosis.97-99 Further, the inconsistencies in these results
indicate that anti-oxLDL antibodies are not an ideal additive biomarker for risk
stratification.
An alternative antigen-specific antibody response studied which also relates
to lipoprotein risk factors is antibodies toward ApoA-I. Antibodies targeting ApoA-I
were connected to CVD as Vuilleumier et al. determined that patients with a history
of acute coronary syndrome had higher levels of anti-ApoA-I IgG.111 Continuing
research, much of it completed by Vuilleumier and his research team, found that
the level of anti-ApoA-I IgG was correlated with CVD progression in patients with
specific cardiovascular co-morbidities112-114 and in patients with preexisting
CVD.115, 116 While these studies indicate a significant relationship between antiApoA-I IgG and future CVD events, conflicting studies have shown no significant
relationship.117-119 Antiochos and colleagues subsequently evaluated a populationbased cohort including over 5000 subjects to further understand the role of antiApoA-I IgG in risk prediction. The results indicated that anti-ApoA-I IgG was
associated with both non-fatal coronary artery disease (CAD) and with all-cause
mortality in this cohort.120, 121 These results point to a potential role for anti-ApoA-I
IgG in CVD prediction; however, this association is not resilient to modifications in
outcome measures or changes in the thresholds of the groups. When evaluating
the relationship between anti-ApoA-I IgG and CAD, anti-ApoA-I IgG was only
predictive of non-fatal CAD; if compared to total CAD or fatal CAD, there was no
longer a relationship. A potential complication was that while the fatal events were
concentrated in the group lacking anti-ApoA-I IgG there were only 25 fatal CAD
events in the study during the average follow-up of 5.6 years.121 Additionally, antiApoA-I IgG only associated with non-fatal CAD when comparing patients above or
below their threshold. When ranges of anti-ApoA-I IgG were evaluated based on
the standard deviation of the population, increased anti-ApoA-I IgG did not predict
non-fatal CAD.121 Taken together, the studies suggest that anti-ApoA-I IgG exhibits
potential as a biomarker for CVD progression, but limitations hinder its utility.
Auto-antibodies targeting antigens outside of the major risk factors of LDL
and HDL have been studied as well. One broad group of antibodies are the antiphospholipid antibodies which include anti-cardiolipin and anti-phosphatidylcholine
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(anti-PC) antibodies. Two reports of anti-cardiolipin antibodies were published in
1996 and 1997; the first found a significant relationship between antibody elevation
and CVD events, while the second publication found a trend but no significant
relationship.122, 123 Evaluation of anti-PC antibodies indicated that decreased
antigen-specific IgM antibodies may play a role in prediction of CVD events in men,
but no relationship was detected in samples from women, which the authors
suspect may occur due to a lack of power as there are few events in this group.124
A separate evaluation of antibodies targeting PC found that only IgA antibodies
correlated with disease outcomes, while IgM and IgG antibodies did not.125 These
reports of mixed correlation between anti-phospholipid antibodies and CVD events
indicate the limitations of this biomarker.
Beyond the autoantibodies discussed thus far, anti-pathogen antibodies
have been studied in the context of CVD. A report by Saikku et al. found that
patients with elevated levels of anti-Chlamydia pneumoniae IgA antibodies were
at increased risk of CVD; however, in an adjusted model accounting for common
cardiovascular risk factors, there was no significant association.126 A separate
study evaluated antibodies targeting cell wall antigens from Chlamydia
pneumoniae and found that IgA antibodies correlated with CVD events, while IgM
and IgG antibodies did not associate.125 A recent evaluation of antibodies to the
microbial flora of the mouth determined that IgG antibodies targeting specific
groups of microorganisms correlated with CVD mortality.127 The association of
these antibodies with disease progression could indicate a role for these
antibodies; however, the relationship between anti-Chlamydia pneumoniae
antibodies and atherosclerosis may occur as a result of the pro-atherosclerotic role
of the bacterium itself as it has been found in atherosclerotic plaques collected
from patients and connected to pro-atherosclerotic changes in endothelial cells
and macrophages.128-130 More research evaluating these potential connections is
needed, including mechanistic analysis of Chlamydia pneumoniae antibodies as
antibody serology does not perfectly correlate to pathogen in the plaque.130
The results of studies evaluating antigen-specific antibodies for the
prediction of CVD are mixed, with conflicting results between many studies,
particularly in studies of auto-antibodies. Because many auto-antigens co-exist in
circulation along with antibodies, an additional measure has been developed to
quantify antibodies bound to antigens in a immune complex (IC).
Two broad strategies are used to detect antigen-specific ICs in patient
samples. These strategies either focus on purification to isolate ICs from the rest
of the sample or a sandwich ELISA used to quantify ICs based on antibody
specificity. In the purification method, samples are separated by the size of the
particles or by binding the immunoglobulin in the complex to a substrate such as
protein A or protein G. When purifying oxLDL ICs, the Lopes-Virella lab utilize both
purification techniques, initially precipitating ICs via polyethylene glycol (PEG)
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centrifugation and then fractionation with either protein G or protein A columns.
The antigen in the ICs are later eluted from the columns with a sodium borate
buffer.131 The collected fractions are then tested for the presence of oxLDL which
indicates its presence in an IC.131 Alternatively, ICs can be directly detected by an
ELISA with capture antibody and secondary antibody such that one antibody binds
the antigen of interest and the other binds the immunoglobulin. For detection of
ICs which include ApoB, the plate is coated with MB47, an anti-ApoB monoclonal
antibody, and incubated with patient samples. The plate is then probed with a
detection antibody specific for either IgG or IgM.108 Both strategies to measure IC
have been tested for their ability to predict CVD risk in patients.
IC containing oxLDL and other modified forms of LDL have been shown to
correlate with disease in patients with diabetes. Serologic analysis of patients with
type 2 diabetes showed that an elevated level of a malondialdehyde modified LDL
(MDA-LDL) in ICs was associated with increased MI events.132 Similar work in type
1 diabetes found relationships between the levels of both oxLDL-ICs and MDALDL-ICs and the occurrence of CVD events over time.133 While the results of these
studies indicate a potential role for oxLDL ICs in CVD prediction, this measurement
may have limited utility in the clinical laboratory due to the specificity of the study
population and the complexity of the assay, as the assay utilizes a multi-step
purification process followed by an ELISA on collected fractions.
Although a sandwich ELISA is a streamlined process of measuring ICs,
these assays have yet to identify an IC which effectively predicts CVD risk.
Measurements of ICs with ApoB in a sandwich ELISA have been studied in two
large trials; however, these trials both showed that ApoB/IgG ICs and ApoB/IgM
ICs were not associated with CVD in a clinically relevant way.105, 108 In one study
ApoB/IgM ICs correlated with CVD events, but when adjusted for common CVD
risk factors, the effect was lost.105 Additional ICs such as β-2-glycoprotein-I
(B2GPI)/IgA ICs and ICs with Chlamydia pneumonia’s lipopolysaccharide have
been studied in the context of CVD, but no predictive values have been established
for these ICs.126, 134, 135
Evaluation of antigen-specific antibodies and antigen-specific ICs has failed
to identify an ideal biomarker for CVD risk prediction. The results with anti-ApoA-I
IgG are the most consistently predictive as multiple trials in multiple populations
indicated that elevation in anti-ApoA-I IgG levels were associated with increased
risk of CVD. However, the largest population-based study demonstrates the
limitations of this assay as the associations within this trial were only significant
when measuring non-fatal events and using a specific threshold for positivity, when
fatal events were included, or when patients were grouped based on the number
of standard deviations from the mean, the predictive value was lost. Nevertheless,
given the promising results with several strategies, continued exploration of
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antigen-specific antibody responses is warranted to understand their potential role
in CVD progression.
1.5

Human anti-animal antibodies

Accurate results from clinical assays are critical to ensuring optimal patient
care for CVD as well as many other health conditions. Interference in these clinical
assays can lead to misdiagnosis and unnecessary treatments. A common form of
assay interference is the presence of antibodies which bind to the assay reagents
and can cause both readings that are improperly high and improperly low. The
discussion in this section will focus on reports of interfering antibodies present
within the literature. Importantly, these interfering antibodies have been reported
in assays used in the diagnosis of myocardial infarction and may potentially
interfere with assays used to measure biomarkers and antigen-specific antibody
responses discussed in previous sections.
Interfering antibodies prevent proper measurement of an analyte. Interfering
antibodies have been found historically including a report of double precipitin rings
formed in the Manchini technique which could be eliminated via absorption with
normal animal serum.136 Many subsequent reports have identified interfering
antibodies, including in cases of suspected CVD where patients were diagnosed
with myocardial infarction based on elevated troponin levels137-139 and a report of
interfering antibodies in an assay for the measurement of an inflammatory
cytokine. 140
A seminal review published in 2002 divided interfering antibodies by their
origin and their mechanism of interference. The primary form of interfering
antibodies in their estimation are heterophilic antibodies (HA). They classify HA as
natural antibodies to their presence in almost all subjects tested and their weak
binding to a broad set of substrates.141 The authors contrasted HA with human
anti-animal antibodies (HAAA) which bind with higher affinity to a specific
antigen.141 Specifically they indicate that HAAA occur as a result of an
immunization event, for example human anti-mouse antibodies (HAMA) often
developed as a result of treatment with therapeutic antibodies derived from
mice.141 While this division has shaped the way interfering antibodies are thought
of and discussed in the literature, tools to reliably differentiate between these
populations are lacking. Levinson and Miller also suggest several related
mechanisms of interference for these antibodies, including patient antibodies that
bind to the capture antibodies in an ELISA and are detected via an antiimmunoglobulin secondary antibody and antibodies that bind to the conjugate in
an interference ELISA.141 However, the mechanism which most commonly impacts
clinical assays and patient care is the cross-linking of capture and detection
antibodies by a interfering antibody which causes elevated readings in the assay,
independent of the analyte concentration.141
12

Inaccurate results obtained due to crosslinking antibodies can lead to
incorrect diagnoses and unnecessary or harmful treatments. Several cases from
the clinical literature highlight the impact of this phenomenon. In one report, a
woman who was feeling unwell underwent laboratory screening and was found to
have an unexpectedly high level of insulin.142 Based on this lab value, she was
admitted to the hospital for inpatient care until subsequent analysis found that this
insulin value was the result of heterophilic antibodies.142 In other cases, patients
were diagnosed with myocardial infarctions, admitted to the hospital, and in 2 of 3
cases given coronary angiography imaging largely based on elevated troponin
values.137-139 The influence of interfering antibodies was confirmed in two of the
three cases as addition of blocking agents decreased signal, while in the third case
the influence of heterophilic antibodies was suspected due to differential results
with different assay kits.137-139 A compilation report by Rotmensch and Cole
described very consequential set of misdiagnoses due to interfering antibodies in
12 women who were diagnosed with cancer due to falsely elevated human
chorionic gonadotropin values.143 In 11 of these women the misdiagnosis lead to
a surgical procedure, with four women undergoing a hysterectomy. The role of
heterophilic antibodies in these women was identified via repeated testing with
different kits, as well as testing the urine in addition to blood.143 These case reports
highlight the potential harm of interfering antibodies in patients; however,
evaluations in a larger population are necessary to fully understand the stmuli
leading to their induction and the subsequent implications of interfering antibodies.
A limited number of large-scale experiments have been completed to
evaluate interfering antibodies in the general population. Andersen and colleague
sought to identify crosslinking antibodies in an ELISA measuring the endometrial
protein PP14. This assay utilizing two mouse monoclonal antibodies found that 44
of 54 male samples had false positives.144 Further analysis showed that this
interference occurred as a result of human antibodies targeting cow IgG which
contaminated the mouse monoclonals used in the ELISA.144 When testing with
pure cow IgG, 99 of 104 subjects had interfering antibodies.144 A separate study
evaluated interfering antibodies in ELISA for the tumor marker, carcinoembryonic
antigen and found 4% of samples had interfering antibodies to the mouse IgG
utilized in the study.145 This result is very different than the Andersen report, an
indication that much is still to be learned concerning these interfering antibodies
present in patient samples.144
1.6

Gaps in knowledge, hypotheses tested, and points discussed

Currently, there are no antigen-specific antibody responses in patients that
are used as a part of CVD risk prediction in the clinic. Researchers have proposed
various antigen-specific antibodies and antigen-specific ICs as biomarkers;
however, none have consistently shown correlations across populations, trials,
and outcome measures. To fill this gap, we propose a novel biomarker for CVD
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risk prediction which has been detected previously in human and mouse samples.
Immune complexes containing ApoA-I and IgG (ApoA-I/IgG ICs) have been
purified from human blood previously by a multistep strategy,146 and have been
detected in samples from auto-immune gld mice.147 Based on these previous
studies identifying ApoA-I/IgG ICs, we sought to explore this factor in the context
of CVD risk prediction.
We initially developed an ELISA to measure ApoA-I/IgG ICs in human
plasma. In Chapter 2, we discuss the results from this ELISA in samples collected
from patients. In a cohort of patients with pre-existing CVD, we determine that
decreased responses in this ELISA are associated with increased CVD events
over a median follow-up of 4.1 years. We find enrichment of the anti-inflammatory
IgG4 subclass within the IgG that contributes to this biomarker during subsequent
characterization studies in samples from blood donors. However, in an analysis of
the assay we determine that the ELISA is not measuring ApoA-I/IgG ICs as
intended, but measuring an interfering antibody targeting goat IgG. This
unexpected finding prompted further study of this interfering antibody response
which associates with CVD outcomes in our study.
In Chapter 3, we evaluate the biomarker and determine it to be a human IgG
anti-goat IgG antibody (HAGA). We initially confirm that the results of the ELISA
are independent of the specificity of the goat capture antibody, and dependent on
the origin species of the capture antibody. In further experimentation, we verify that
IgG is the plasma factor which binds to goat IgG in this assay. We then perform
initial characterization of HAGA by studying its binding by western blot and biolayer
interferometry. These results indicate that HAGA are high affinity antibodies that
target the heavy chain of goat IgG.
The research within this dissertation identifies a novel factor for evaluation in
CVD risk calculations. In discussing the results of these studies, we will describe
study limitations and provide details of future directions to explore based on these
findings. Continued studies include: assessment of the association between
HAGAs in a community-based prospective cohort with subjects whom are free
from CVD and future CVD events; identification of epitopes of goat IgG targeted
by HAGA; evaluation of potential mechanism of action for HAGA; and
characterization of human anti-rabbit antibodies identified in this work. The
conclusions of these studies are important beyond the potential use of HAGAs in
CVD risk prediction because continued evaluation of this plasma analyte may
indicate a mechanistic role of HAGAs in CVD progression and therefore a more
nuanced understanding of nature of CVD generally.
1.7

Serological assays to measure anti-pathogen antibodies.

Serological analysis of anti-pathogen antibodies can provide guidance for
infectious risk in patients. A history of infection or vaccination can lead to the
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presence of anti-pathogen antibodies and potentially protective immunity. Analysis
after the outbreak of Severe Acute Respiratory Syndrome Coronavirus (SARSCoV) in 2002 and 2003 indicated that infected patients developed neutralizing antiSARS-CoV antibodies after infection, a potential indication of protection from reinfection. Subsequently, a related virus SARS-CoV-2 emerged and caused a
global pandemic, during which serological assays were developed to identify
patients with previous SARS-CoV-2 infection who may be resistant to re-infection.
In this section I will briefly introduce the use of serological analysis to detect antipathogen antibodies and describe the use of these assays during the SARS-CoV2 pandemic.
The presence of anti-pathogen antibodies can indicate protection from
subsequent infection. During the course of an infection the immune system will
often respond to the pathogen and produce antibodies targeting the infectious
agent. For specific pathogens such as varicella-zoster virus, which is generally
suppressed after initial infection, the presence of these antibodies is used clinically
as an indication that the subject is at a very low risk of re-infection with the virus.148,
149
Serological analysis of anti-pathogen antibodies can also be used as a marker
of vaccine generated protective immunity. For hepatitis B, health care workers are
often screened after vaccination to ensure the presence of antibodies which are
indicative of a successful vaccination.150
Serological studies indicate the presence of anti-SARS-CoV antibodies in
convalescent patients. Patients with a probable history of SARS-CoV infection
indicate that 83.3% of these patients had detectable anti-SARS-CoV antibodies in
contrast to 0% of control subjects.151 Subsequent analysis of patient samples
indicates that infected patients develop neutralizing antibodies, or antibodies that
can prevent viral infection of cells.152, 153 Importantly, evaluation of SARS-CoV
seropositivity indicates that IgG antibodies targeting the virus are maintained, as
89.6% of subjects still had detectable IgG a year after infection, and over 50% of
subjects were positive beyond 764 days.154 The ready detection of anti-pathogen
antibodies in combination with the neutralizing nature of the antibodies and the
longevity of the immune response indicate that a protective immune response is
likely developed in patients previously infected with SARS-CoV which may protect
patients after initial infection.
During the SARS-CoV-2 pandemic, researchers developed serological
assays to measure protective immunity to SARS-CoV-2. Related to the original
SARS-CoV virus, the SARS-CoV-2 virus was first identified in China and quickly
spread around the world. As the virus began to spread globally researchers
developed and employed serology testing for the SARS-CoV-2 virus to enable
identification of patients previously infected with SARS-CoV-2, including patients
who may not have been diagnosed via PCR testing during the active infection. 155,
156
The developed assays were validated as they readily differentiated between
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subjects with and without a known history of infection.155, 156 Subsequent use of
these validated assays suggest that the true rate of SARS-CoV-2 infection may be
up to ten times greater than the reported rate of PCR positivity.157, 158 Additionally,
analysis suggest that the presence of anti-SARS-CoV-2 antibodies in a serological
assay is a strong indicator of protection from infection and prospective studies
have found that patients positive for anti-SARS-CoV-2 antibodies are at a
decreased risk for re-infection.159-164
In chapter 4, I describe the optimization of a high-throughput assay to
measure anti-SARS-CoV-2 antibodies based on previously established protocols.
Prior to the SARS-CoV-2 pandemic, our laboratory established an automated plate
washing and dispensing protocol to perform high-throughput ELISAs. During the
pandemic, while general research was shuttered at the University of Kentucky, we
optimized a protocol for high throughput analysis of SARS-CoV-2 antibodies.
1.8

Epitope-specific immunomodulation with doxorubicin liposomes

Liposomal doxorubicin represents an alternative therapeutic strategy to treat
antibody mediated autoimmune disease. The binding of autoantibodies to specific
autoantigens leads to the development of certain autoimmune diseases in patients.
These autoantibodies can induce disease via several mechanisms inducing
inflammation, which prompts tissue damage, or by preventing binding of a protein
to its designated target, disrupting adhesion or signaling.165 While the
pathophysiology of these diseases centers on the role of the specific
autoantibodies, the clinically approved therapeutic strategies focus on nonepitope-specific immunosuppression via broadly active therapeutics resulting in an
overall reduction in all B cells and antibodies. Liposomal doxorubicin represents
an alternative therapeutic strategy for immunosuppression, where an autoantigen
can be linked to the liposome and injected to deliver an epitope-specific payload
to distinct cells. This potential of this strategy is based on evidence that liposomal
doxorubicin effectively blocks the development of a novel antibody response in an
epitope-specific manner and can suppress a preexisting IgE response.166-170 In this
section, I will describe the pathologic effects of specific epitope-specific antibodies,
the current therapeutic strategies and introduce the potential utility of liposomal
doxorubicin for epitope-specific immune suppression.
Pathologic epitope-specific antibodies cause harm in patients. Though
immunologic tolerance is intended to prevent the development of antibodies
targeting self-antigens, autoantibodies develop in some patients and are known to
cause specific forms of autoimmune disease.165 These autoantibodies include antiα3(IV) collagen antibodies which lead to the development of Goodpasture’s
syndrome, anti-acetylcholine receptor (AChR) antibodies which can induce
myasthenia gravis, and anti-desmoglein antibodies which cause Pemphigus
Vulgaris.171-173 The mechanistic link between these pathologic antibodies and
disease varies as antibodies have several different roles as components of the
16

immune systems. For example, in Goodpasture’s disease the autoantibodies bind
to a specific collagen, which triggers the complement fixation and immune cell
activation.174 Both processes lead to local inflammation and tissue damage which
is concentrated in the lungs and kidneys.174 In contrast, Pemphigus Vulgaris does
not appear to rely on inflammation, but the binding of the anti-desmoglein
antibodies both sterically inhibits the crosslinking of desmoglein proteins and leads
to the internalization of desmoglein into the cell.175 The consequence of this lack
of desmoglein adhesion is severe blisters on the skin.175 The effects of anti-AChR
receptor antibodies appear to be a combination of these pathways, with effects
driven by steric hindrance blocking the receptor, internalization of crosslinked
receptors and complement fixation, all of which combine to induce weakness due
to a lack of proper signaling at the neuromuscular junction.172 Importantly, it is the
binding of the epitope specific antibody to the target which initiate the development
of the disease, the later effector functions and disease phenotype arise from this
binding.
Despite epitope-specific effects, the clinically approved therapeutics for
antibody mediated auto-immune disease center on epitope-independent
therapeutics. In Goodpasture’s syndrome the recommended treatment strategies
focus on broad immune-suppressive treatments with corticosteroids,
cyclophosphamide and plasmapheresis.176, 177 These treatments will either induce
general non-epitope specific immunosuppression or in the case of plasmapheresis
reduce total IgG, with no selectivity for the pathogenic antibodies.176, 177 Similarly
for Pemphigus Vulgaris, the treatment strategies begin with corticosteroid
treatment with the addition of adjuvant immunosuppressive therapy including
azathioprine, mycophenolate mofetil, or an anti B cell monoclonal antibody
Rituximab.178 This monoclonal antibody is targeted to CD20 resulting in antibody
dependent cell cytotoxicity (ADCC).179 CD20 is only present on B cells, which are
lymphocytes that produce antibodies, and therefore rituximab results in the loss of
any B cell that the therapy interacts with leading to a suppression of all B cells and
a reduction of all antibodies, not a selective inhibition of the anti-desmoglein
antibodies.178, 179 Further, the most recent recommendations for treatment of
Myasthenia Gravis include the anti-B cell agent rituximab early in the treatment
protocols along with other broadly active immunosuppressive agents such as
Eculizumab to target the complement inflammation pathway, and immune
checkpoint inhibitors to prevent full cell activation.180 Despite the benefit of these
therapeutic strategies, they induce broad immunosuppression which can
predispose patients to infections and reduce the availably of immunoproteins.
Specifically, evaluations of corticosteroid therapy demonstrate an increased rate
of infection, one specific report indicates that patients with rheumatoid arthritis
treated with 5 mg of prednisolone are at an 30% increased risk of infection after
only 30 days on therapy. 181, 182 Additionally, rituximab is potentially associated with
severe hypogammaglobulinemia, a severely reduced level of total IgG and many
studies report the need for IgG replacement in these patients.183, 184 Therefore,
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strategies that selectively suppress epitope-specific immune responses will have
a profound impact on reducing the burden of disease while supporting
maintenance of an effective immune response to prevent the risk of infections or
the need for immune reconstitution.
Doxorubicin liposomes have been shown to suppress the development of
epitope-specific antibody responses in mice. Doxorubicin liposomes stabilized by
polyethylene glycol (PEG) were initially developed as cancer therapeutics as they
exhibit improved efficacy and safety over a cocktail of drugs including free
doxorubicin.185 Importantly, with specific dosages and formulations, PEG
liposomes are known to induce an Accelerated Blood Clearance (ABC) effect
where subsequent dosages of liposomes following the initial dose are rapidly
cleared from the body; however, the use of doxorubicin liposomes coated with
PEG at the same formulation and dosage fails to induce this ABC effect.166-168
Subsequent investigations show that a mechanism of enhanced clearance is due
to immunoglobulins targeting PEG, while increased circulation is due to a reduction
in anti-PEG antibodies.167, 168 This observation indicates that doxorubicin
liposomes are potentially suppressing the antibody response to PEG.167, 168
Additionally, doxorubicin liposomes have been shown to impact the development
of an antibody response to protein antigens, specifically the model antigen
ovalbumin. Oja et al. determined that injection of ovalbumin liposomes with
doxorubicin effectively suppresses the ABC effect of repeated injection and
suppressed the antibody response to ovalbumin when administered at appropriate
concentrations of antigen and doxorubicin.169 Importantly, this report also indicates
that the effect is somewhat epitope specific as injection of doxorubicin liposomes
lacking ovalbumin does not suppress the immune response to ovalbumin injected
on separate liposomes at a doxorubicin dose of 4 mg/kg.169 In an additional
experiment to evaluate specificity, Oja and colleagues show that the immune
response to hen egg lysozyme (HEL) is similar to control levels when HEL
proteoliposomes are co-injected with 4 mg/kg of doxorubicin liposomes labeled
with ovalbumin, a doxorubicin dose known to fully suppress the immune response
to the linked ovalbumin antigen.169 While the reports detailed thus far have focused
on the inhibition of a novel antibody response, a report by Ichikawa et al. sought
to explore the effect of doxorubicin liposomes on a pre-existing antibody
response.170 The results show a partial suppression of IgE antibodies targeting
ovalbumin in pre-sensitized mice when treated with doxorubicin liposomes labeled
with ovalbumin, demonstrating that these liposomes can impact a pre-existing
immune response.170 Furthermore, they show co-localization of fluorescentlylabeled ovalbumin liposomes and B cells in pre-sensitized mice, an indication of
liposomal targeting which provides a potential mechanism for the effect of
doxorubicin liposomes in targeted immunosuppression.170
In chapter 5, I describe an experiment to evaluate the use of doxorubicin
liposomes to induce epitope-specific suppression to a pre-existing immune
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response in mice. This experiment was designed to test the effect of a single
injection of doxorubicin liposomes on pre-existing immune responses to two
antigens with potential clinical relevance, the carbohydrates which mark red blood
cells of blood group A and a peptide antigen derived from mouse ApoA-I which is
homologous to a region targeted by human anti-ApoA-I IgG.186, 187 We initially
immunized mice with either the carbohydrate antigen alone, or both the
carbohydrate and the peptide, followed by an injection with antigen-conjugated
liposomal doxorubicin. The mice were subsequently re-immunized and the
immune response after re-immunization was utilized as a marker of the effect of
suppression. Although additional experimental optimization and development are
required, the results presented in this chapter 5 support the potential utility of
doxorubicin liposomes as an epitope-specific immunomodulatory strategy.
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Table 1-1 Distribution of immunoglobulin classes in human circulation. Values
from Schroeder and Cavachini.102
Antibody
Percent of Serum
Class
Antibodies
IgG
75%
IgM
10%
IgA
15%
IgD
<0.5%
IgE
<0.01%
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CHAPTER 2. ASSOCIATION BETWEEN A HUMAN IMMUNOGLOBULIN G
ANTIBODY AND ADVERSE CARDIOVASCULAR EVENTS
2.1

Abstract

Objective: The immune response is linked to the progression of
atherosclerotic cardiovascular disease (CVD). Free autoantibodies targeting
ApoA-I (apolipoprotein A-I) have been identified as a component of the
inflammatory milieu in patients and have a moderate association with CVD
progression. Based on the presence of these antibodies and the high
concentration of circulating ApoA-I, we hypothesized that antibodies bound to
ApoA-I as an immune complex would be predictive of incident adverse CVD
events.
Approach and Results: The ELISA developed to test for ApoA-I/IgG ICs was
utilized in 3 patient populations. Analysis was performed in a population of 359
patients with a history of coronary artery disease (CAD) who experienced a total
of 71 incident adverse CVD events (death, myocardial infarction, and stroke) over
a median 4.1-year follow-up. In Cox proportional hazard regression analysis, low
response in this assay was an independent predictor of adverse cardiovascular
outcomes after adjustment for age, sex, diabetes mellitus, estimated glomerular
filtration rate, presence of obstructive CAD, heart failure, total cholesterol, and HDL
(high-density lipoprotein) cholesterol (adjusted hazard ratio of 1.90 [95% CI, 1.03–
3.49; p=0.038] between the lowest and the highest tertiles). Analysis of the IgG
subclasses which contribute to this analyte find enrichment in the anti-inflammatory
subclass IgG4 as compared to levels of inflammatory IgG1. Various purification
techniques were utilized in attempts to isolate this analyte; however, no method
was able to fully isolate this biomarker from IgG. This prompted an evaluation of
the assay via exchange of capture antibodies and the determination that the
analyte appears to be an interfering antibody from patients which binds to goat
IgG.
Conclusions: Low levels of an interfering anti-goat IgG antibody in plasma
are associated with an increased risk of adverse CVD events in patients with CAD,
indicating the potential of this antibody response as a biomarker to predict CVD
progression and prompting further exploration of this interfering antibody.
2.2

Introduction

The immune response is linked to the pathogenesis of atherosclerotic
cardiovascular disease (CVD),65, 188 with both innate and adaptive immunity
implicated in its progression.189, 190 Furthermore, patients with chronic
inflammatory conditions, such as autoimmune disorders, have an increased risk of
CVD.49 Characterization of the autoantigens and epitopes responsible for inducing

specific immune responses have led to a number of studies focused on antibodies
targeting oxLDL (oxidized forms of low-density lipoprotein) 97-99, 103-110, 191 and
ApoA-I (apolipoprotein A-I).111-121, 187, 192-197
Anti-ApoA-I antibodies have been identified in several diseases;111-113, 118, 195197
however, their role in disease progression is poorly defined. A communitybased cohort study of over 5000 subjects, found that 20% of subjects tested
positive for anti-ApoA-I antibodies and their presence correlated with development
of incident non-fatal coronary artery disease (CAD).121 While this report may seem
indicative of an association between anti-ApoA-I IgG and CVD events in a general
population, a deeper evaluation shows that the correlation is limited to non-fatal
CAD, as total CAD and fatal CAD did not correlate.121 This report highlights the
limitations of observed associations between anti-ApoA-I IgG and CVD.
The relatively low prevalence of anti-ApoA-I IgG in patients and the high
concentration of ApoA-I in circulation encouraged us to characterize immune
complexes (ICs) formed between ApoA-I and IgG (ApoA-I/IgG ICs). While previous
reports in mice147, 198 and patients indicate the presence of ApoA-I/IgG ICs in
blood,146, 199, 200 these complexes are not well characterized and have not been
associated with CVD. To test our hypothesis that ApoA-I/IgG ICs can be readily
quantified in plasma and potentially correlate with CVD progression, we developed
an ELISA to detect these ICs and utilized it in a cohort of well-characterized
patients with CAD to determine the relationship with disease progression. We
subsequently performed further evaluation in patients with serial blood draws after
a myocardial infarction (MI) and in blood donor subjects with large sample
volumes.
2.3

Materials and Methods

Human Samples
Patients With CAD (Cohort 1): Samples were obtained from 359 patients
with CAD enrolled in the Emory Cardiovascular Biobank, a prospective cohort of
20- to 90-year-old patients who underwent elective or emergent cardiac
catheterization.201 Arterial blood was collected into EDTA tubes and plasma
isolated from whole blood prior to storage until use at −80°C. All subjects were
provided informed consent.
Hypertension, hypercholesterolemia, and diabetes mellitus were defined
according to the Joint National Committee, Adult Treatment Panel III, and
American Diabetes Association criteria, respectively.33, 202, 203 All coronary
angiograms were scored for luminal narrowing using a modified American Heart
Association/American College of Cardiology classification.204 Obstructive CAD
was defined as visible plaque resulting in at least 50% luminal stenosis in at least
1 epicardial vessel. Those with a history of coronary artery bypass grafting or
percutaneous coronary intervention were all labeled as having obstructive CAD.
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Estimated glomerular filtration rate was calculated using the Chronic Kidney
Disease Epidemiology Collaboration equation. Heart failure was defined by the
presence of self-reported history of heart failure or physician diagnosis of heart
failure noted in medical record irrespective of ejection fraction. History of MI was
diagnosed according to the American College of Cardiology/American Heart
Association guidelines as self-reported chest pain and evidence of cardiac
ischemia on 12-lead electrocardiogram or elevated cardiac enzymes greater than
twice the upper limit of normal with angiographic findings consistent with MI
diagnosis.
Patients enrolled in the Emory Cardiovascular Biobank, a prospective
cohort of patients undergoing left heart catheterization for suspected or confirmed
CAD at 3 Emory Healthcare sites in Atlanta, GA, were followed for determination
of major adverse cardiovascular events (death/MI/stroke). Participants were
interviewed to collect demographic characteristics, medical history, medication
use, and behavioral habits. Risk-factor prevalence was determined by physician
diagnosis and treatment for hypertension, hyperlipidemia, and diabetes mellitus,
and these factors were also defined according to the Joint National Committee,
Adult Treatment Panel III, and American Diabetes Association criteria,33, 202, 203
respectively, and smoking habits were recorded. History of significant CAD was
defined as at least 1 major epicardial vessel with ≥50% stenosis. Medical records
and International Classification of Diseases, Ninth Revision (ICD-9) diagnostic
codes were reviewed to confirm self-reported medical history. Cause of death was
adjudicated by 2 independent cardiologists blinded to the data with a third arbitrator
in case of disagreement. MI was diagnosed according to the American College of
Cardiology/American Heart Association guidelines as presence of self-reported
chest pain and evidence of cardiac ischemia on 12-lead electrocardiogram or
elevated cardiac enzymes greater than twice the upper limit of normal with
angiographic findings consistent with acute MI diagnosis. Outcome data were
obtained by phone contact, electronic medical record review, and data from the
social security death index and state records. Adjudication was conducted by
personnel blinded to the data. The study was approved by the institutional review
board at Emory University (Atlanta, GA). All subjects provided written informed
consent at the time of enrollment.
Patients with Acute MI (Cohort 2) Plasma samples from patients enrolled
in the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction
in Acute Coronary Syndrome), who presented with a non-ST-segment elevation
MI (nSTEMI) and had blood drawn at presentation while undergoing percutaneous
coronary intervention and 30 days after presentation. Patients were enrolled if their
symptoms began within 24 hours before hospital presentation if they had evidence
of acute coronary syndrome without ST-segment elevation. Complete details of
this study are available.205 Patient samples were de-identified when shared with
our laboratory.
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Blood Donor Subjects During the blood donation process at the Kentucky
Blood Center, EDTA tubes and clotting tubes are filled. Excess sample tubes
reserved for potential testing and are stored at 4°C for 7 days. Samples that were
not required for additional testing were provided to our laboratory. Upon receiving
samples, plasma from EDTA tubes or serum from clotting tubes was separated
from the whole blood via centrifugation and stored at −80°C until assayed.
Samples are completely de-identified.
ELISA methods
Analyte ELISA Streptavidin-coated preblocked plates (Thermofisher,
15124) were washed 3 times with 200 µL of PBS containing 0.1% tween (PBS-T)
before coating with 500 fmol (72 ng) of biotinylated goat anti-ApoA-I IgG (Abcam,
ab27630) in 100 µL of in PBS-T. Plates were incubated at 37°C for 2 hours and
subsequently washed 6 times with PBS-T. Plasma samples diluted 1:200 in PBS
with 0.1% casein (PBS-C) were added to the wells and incubated at 37°C for 30
minutes. After 6 washes with PBS-T, 100 μL of horseradish peroxidase (HRP)conjugated anti-Human IgG (Abcam, ab7153) was added at a dilution of 1:4000 in
PBS-C and incubated for 30 minutes at 37°C. After a final 6 washes with PBS-T,
100 μL of room temperature (RT) tetramethylbenzidine (Rockland
Immunochemical) was added and allowed to react for 30 minutes at RT in the dark.
The reaction was stopped using 100 μL of 0.5 M H2SO4 and absorbance was
measured at 450 nm (BioTek, Synergy Hybrid Reader). All samples were analyzed
in duplicate or greater.
Coefficients of Variation Wells of the streptavidin plates were either coated
with biotinylated goat anti-ApoA-I IgG or left uncoated. Plasma from 18 blood donor
subjects was diluted 1:200 with PBS-C and tested in 12 coated well and 12
uncoated wells on an individual day. This was repeated until all 18 subjects had
been tested 3 times. Results from these replicates are shown in Figure 2.1. Wells
from subject 1 which had absorbance values over the instrument maximum were
graphed as 4.0, and due to the frequent maximum values observed, subject 1 was
excluded from any coefficient of variation analysis (CV). CV was calculated by
taking the standard deviation of samples and dividing it by the average of the
samples, for intra-assay CV the 12 values on a single day are utilized, for interassay CV all 36 values are used in the calculation. The average intra-assay CV
was found to be 9.7 and the average inter-assay CV was determined to be 14.1%.
Assay Linearity The linearity of assay was evaluated in 12 samples at
dilutions ranging from 1:50 to 1:400 and compared with capture-antibody-free wells
at each plasma dilution (Figure 2.2A). One sample exhibited very high absorbance
across all dilutions and was further diluted down to 1:12,800 (Figure 2.2A). Given
the differing concentrations of plasma at each dilution, a second linearity assay
with constant plasma concentration of a 1:200 was completed by mixing diluted
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plasma from subjects with high responses and low responses at ratios of 4:0, 3:1,
2:2, 1:3, and 0:4 (Figure 2.2B).
Plate Washer Procedure for analyte ELISA was completed with the use of
an EL-406 Plate Washer Dispenser (Biotek) attached to a syringe pump and
Biostack 3 (Biotek). For these experiments, assay plates were utilized at positions
1, 2, 6 and 10 in the Biostack, with non-assay plates at positions 3, 4, 5, 7, 8, and
9 to control for timing. Absorbance values from assay plates across the stack were
used to calculate CV values. An additional assay plate was also evaluated
manually during this process.
Capture antibody exchange After initial washes the plates were coated with
one of three biotinylated goat capture antibodies: goat anti-ApoA-I IgG (Abcam,
ab27630), goat anti-ApoB IgG (Abcam, ab20898), or goat anti-GFP IgG (Abcam,
ab6658). Each antibody was diluted so that the 100 µL coating volume contained
500 fmol (72 ng) of capture antibody, additional control wells were left uncoated.
Control anti-goat IgG (HRP) ab(97105) 1-20,000 was used in plasma free wells as
a positive control during the secondary antibody step. Additionally, the secondary
antibody incubation in this experiment was extended to 60 minutes.
As a control for ICs, artificial ICs were created by mixing ApoA-I (Athens
Research and Technology 16-16-120101) and rabbit anti-ApoA-I IgG (Millipore
Sigma, 178422) in a 2:1 ratio and adding 100 µL of this mixture, containing 1 pmol
of ApoA-I to wells. These artificial immune complexes were added after the coated
plates were washed, in the same step as diluted human plasma. For detection antirabbit IgG (ab6721) was utilized.
IgG Subclass Composition The concentration of each IgG subclass within
patient plasma was determined via an IgG subclass ELISA kit (Thermo Fisher
991000) according to manufacturer’s instructions. To measure the subclass of IgG
which contribute to the analyte, subclass-specific secondary antibodies were used.
High-binding plates (Microlon 600) were washed 3 times with a Na2CO3 buffer (9.7
pH, 0.05 M) and coated for 2 hours at 37°C with 50 μL of a 1:500 dilution of antiApoA-I antibody in the Na2CO3 buffer. The plates were washed 6 times with PBST then blocked with 200 µL of PBS-C for 1 hour at 37°C before 2 washes with PBST. Then, 100 μL of plasma was added at dilutions ranging from 1:50 to 1:4000 in
PBS-C and incubated for 30 minutes at 37°C. The plates were washed 6 times
with PBS-T and 100 μL of secondary antibodies were added, diluted as follows:
anti-Human IgG1 HRP (Abcam, ab99774) 1:500; anti-Human IgG2 HRP (Abcam,
ab99779) 1:500; anti-Human IgG3 HRP (Abcam, ab99829) 1:500; anti-Human
IgG4 HRP (Abcam, ab99817) 1:4000. After incubation for 30 minutes with
secondary antibodies, the plates were washed, developed with TMB, quenched
with H2SO4, and the absorbance measured at 450 nm. All samples were run in
duplicate. The resulting absorbance (A450) was compared with standard curves of
immobilized subclass control antibodies on a high-binding plate, IgG1 (Abcam,
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ab90283), IgG2 (Abcam 90284), IgG3 (Abcam, ab118426), and IgG4 (Abcam,
ab90286). Where IgG1 was undetectable in the range of quantifiable IgG4, the
lowest value on the standard curve for IgG1 was substituted and plotted as the
IgG1 value and used in the ratio calculation.
ApoA-I Concentration High-binding plates were washed with Na2CO3
buffer 3 times and coated with 50 μL of a 1:1000 dilution of anti-ApoA-I in Na2CO3
buffer for 1 hour at 37°C. Plates were washed 6 times with PBS-T and blocked
with PBS containing 1% BSA and 0.1% Tween (PBS-B) for 1 hour at 37°C before
2 washes with PBS-T. Samples were diluted 1:100,000 in PBS-B, and 100 μL of
diluted plasma was added to each well and incubated for 30 minutes at 37°C. After
6 washes with PBS-T, 100 μL of anti-ApoA-I (Millipore Sigma, 178422), diluted
1:2000 in PBS-B, was added and incubated for 30 minutes at 37°C. After 6 washes
with PBS-T, 100 μL of anti-rabbit IgG HRP (Abcam, ab6721) diluted 1:20,000 in
PBS-B was added and incubated for 30 minutes at 37°C. The plates were then
washed, developed with tetramethylbenzidine, quenched with H2SO4 and the
absorbance measured at 450 nm. Samples were analyzed in duplicate with a
standard curve on each plate using purified human ApoA-I (Athens Research and
Technology 16-16-120101).
Total IgG Concentration High-binding plates were washed with Na2CO3
buffer 3 times and coated with 50 μL of anti-IgG (Abcam, ab102421) diluted 1:500
in Na2CO3 buffer. The plates were incubated for 1 hour at 37°C, then washed 6
times with PBS-T before blocking for 1 hour at 37°C with PBS-C. After blocking,
the plates were washed 2 times with PBS-T and 100 μL of sample diluted
1:1,000,000 in PBS-C was added and incubated for 30 minutes at 37°C. After 6
washes with PBS-T, 100 μL of a 1:4000 dilution of anti-human IgG HRP (Abcam,
ab7153) in PBS-C was added to each well and incubated for 30 minutes at 37°C.
The plates were then washed, developed with tetramethylbenzidine, quenched
with H2SO4, and the absorbance measured at 450 nm. Samples were analyzed in
duplicate with a standard curve on each plate containing human IgG (Gene Script,
A01006).
Sample purification procedures
DEAE ion exchange column Serum is diluted 1:5 with 0.01 M phosphate
buffer in preparation for use. DEAE resin (Cytiva, Formerly GE-Healthcare, 170500-01) in a column is rinsed with 0.01 M phosphate buffer prior to the addition
of the diluted serum. After the addition of serum buffers with increasing NaCl
concentrations were added in a stepwise fashion. Elution was collected and stored
for analysis.
Hydrophobic interaction chromatography Sample is prepared for
separation by a 1:5 with Tris buffer (0.01 M Tris, 0.001 M EDTA and 0.2% Sodium
Azide) prior to dialyzed against Tris buffer. After dialysis, (NH4)2SO4 is added to
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the sample to produce a concentration of 1 M (NH4)2SO4. HiTrap phenyl HP
column (Cytiva, Formerly GE-Healthcare, 17-1351-01) is prepared by washing
with Tris buffer and by Tris buffer containing 1 M (NH4)2SO4. Centrifuge clarified
sample is loaded on the column followed by washes with decreasing quantities of
(NH4)2SO4 via a stepwise elution strategy. Elution is collected and stored for
analysis via ELISA. This procedure was repeated with Tris buffers at a pH of 7, 5.2
and 4.5.
Sucrose Gradient Centrifugation Sucrose solutions from 80% to 10%,
with 10% steps between layers, were added to an ultracentrifuge tube beginning
with 80% sucrose. Between each layer the tube was covered in parafilm and frozen
at -80 °C. Tubes containing the 7 layers were slowly thawed and plasma carefully
added to top of tube. Tubes are then centrifuged for 15.5 hours at 160,000 g in a
50.4 TI rotor on a Beckman XL-90 Ultracentrifuge with the temperature set to 4 °C.
Fractions are then collected by pipetting from the top of the tube.
Collected fractions were analyzed by ELISA assay based on the procedures
described previously in this chapter. All fractions from a single purification strategy
were diluted identically to enable comparisons from fraction to fraction. Incubation
time with secondary antibody may be extended to 60 minutes. Absorbance A450
values were normalized within a single run based on the equation below, these
normalized values are plotted to ease the comparison of the elution profiles.
Normalized Absorbance =

Statistical Analysis

𝐴𝐴450 Fraction − 𝐴𝐴450 minimum
𝐴𝐴450 maximum − 𝐴𝐴450 minimum

Analysis was completed with either GraphPad Prism or SPSS. Spearman
and Pearson were used to correlate analyte levels with IgG or ApoA-I and clinical
characteristics from patients with CAD. Subject characteristics were reported as
descriptive statistics with means and SDs. Kaplan-Meier curves and Cox
regression models were used to examine the association between analyte levels
and the composite outcome of death/MI/stroke. Cox regression models were
adjusted for age, sex, diabetes mellitus, estimated glomerular filtration rate,
presence of obstructive CAD, heart failure, total cholesterol, and HDL cholesterol.
Characteristics incorporated in multivariable analyses included variables that
correlated in bivariate analysis with the outcome studied. All tests were considered
statistically significant when P<0.05.
2.4

Results

For evaluation of ApoA-I/IgG ICs as a potential biomarker for CVD
progression we completed the ELISA in a well characterized cohort of 359 patients
with a history of CAD. Demographic and clinical characteristics are shown in Table
2-1; the mean age was 64 years, 65% males, 24% were Black. Of the cohort, 88%
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had a history of hypertension, 77% had hyperlipidemia, and 34% had diabetes
mellitus. Approximately 93% of the 359 plasma samples exhibit elevated levels of
analyte in the assay (Figure 2.3A). No associations were observed between the
response in the ELISA and either the demographic characteristics or
cardiovascular risk factors, including body mass index, blood pressure, clinical
history, hyperlipidemia, cholesterol level, and left ventricular function. There was
also no association between the results of our ELISA and the concentration of the
inflammatory marker C-reactive protein (CRP), measured as high sensitivity CRP
(hs-CRP), which was available in 54% of patients Table 2-2.
Subsequently, patients were divided into tertiles based on their response in
our ELISA for determination of the association of analyte levels with CVD events.
There were 71 adverse CVD events in this cohort defined as all-cause mortality,
non-fatal MI and non-fatal stroke during a median 4.1 year (interquartile range,
1.2–6.0 years) follow-up. Kaplan-Meier curves for the association between analyte
tertiles and the adverse CVD events are shown in Figure 2.3B. The rate was
higher in those with lower ELISA response (unadjusted hazard ratio 2.02 [95% CI,
1.11–3.66; p=0.021] between the lowest and the highest tertile; Figure 2.3C). After
Cox proportional hazards regression analysis adjusted for age, sex, diabetes
mellitus, hypertension, estimated glomerular filtration rate, presence of obstructive
CAD, heart failure, HDL cholesterol, and total cholesterol, low analyte levels
remained an independent predictor of incident adverse events (hazard ratio 1.90
[95% CI, 1.03–3.49; p=0.038] for the lowest versus the highest tertile; Figure
2.3C).
To further analyze this biomarker, the persistence 30 days after an MI was
determined in samples collected from 58 subjects with nSTEMI in Cohort
2.205 While Wilcoxon matched-paired test finds a statistical difference between
these two timepoints (p = 0.0128), the median values are highly similar between
the two groups (median baseline = 0.24, median 30 days = 0.25) (Figure 2.4A).
Additionally, correlation analysis indicates a strong association between these two
measurements (Spearman correlation coefficient [rs]=0.92; Figure 2.4B).
More in-depth characterization was performed in the larger volumes of
plasma available from blood donors. An evaluation of 104 blood donor samples
indicates that all samples had detectable response in this ELISA (Figure 2.5A).
No correlation was observed between analyte levels and the total ApoA-I
concentration (median±SD: 100±42 mg/dL; rs=0.008; Figure 2.5B) and a weak
correlation was observed between analyte levels and IgG concentrations
(mean±SD: 9.5±2.7 mg/mL; rs=0.39; Figure 2.5C).
Next, we sought to characterize the antibody subclass composition in total
plasma and the IgG subclasses which contributed to the analyte. This was
performed in 16 samples from the Kentucky Blood Center, 8 with a high ELISA
response when measured on a high binding plate and 8 samples with low
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responses. The IgG subclasses differ in their inflammatory effect with some
subclasses having inflammatory effects (IgG1, IgG2, IgG3) while IgG4 is generally
associated with anti-inflammatory effects.102 The subclass composition in plasma
of all 16 subjects was within the clinically accepted range (Figure 2.6A).206
Subjects with high analyte levels exhibited a compositional profile for IgG1, IgG2,
IgG3, and IgG4 of 60%, 25%, 9%, and 6%, respectively. Although IgG4 exhibited
the lowest plasma concentration, it trended higher in plasma from subjects with
high analyte levels as compared to subjects with low analyte levels (48 versus 14
mg/dL; Figure 2.6B). Quantification of the IgG subclasses within the analyte
indicates that 7 of the 8 samples exhibited measurable IgG4 concentrations (>240
ng/mL) at a 1:50 dilution of serum, whereas IgG3 was the only subclass detected
contributing to the analyte in the eighth subject. IgG4 concentrations within the
analyte were similar or greater than IgG1 in 6 of 7 subjects (Figure 2.6C), which
is highlighted by changes in the IgG1/IgG4 ratio. The ratio of IgG1/IgG4 in the
analyte was lower (median of 0.30) than the ratio in plasma from subjects with high
levels of analyte (median of 9.9, Kruskal-Wallis test with Dunn’s multiple
comparison p = 0.023) and from subjects with analyte levels (median of 31, p <
0.001) (Figure 2.6D).
For potential evaluation of analyte levels in a larger cohort we evaluated the
use of an automated assay plate washer and dispenser in this ELISA. Completion
of the ELISA via a manual process limits the number of samples which can be
assayed at a given time, generally we evaluate 4 assay plates at a time which
allows for the assessment of 160 samples total with 40 samples per assay plate.
To extend the number of samples which can be measured at a given time, we
utilized a plate washer dispenser system attached to a microplate stacker that
presents and retrieves assay plates from washer dispenser system from a stack
of up to 30 plates. Initial evaluation of this system based on the established
protocol found high variability across the stack with mean CV value of 13% (SD of
2.0) (Figure 2.7A). In an attempt to decrease variability, we altered the
methodology to extend the secondary antibody incubation from 30 minutes to 60
minutes, while maintaining the other steps of the procedure (Figure 2.7B). This
extended incubation decreased the variability as measured by CV (mean 10%, SD
of 2.6, p < 0.0001, paired T test) (Figure 2.7C). Importantly, while absorbance
values as increased in samples after the extended incubation, there is a strong
correlation (rs = 1.00) between the median values observed either with the original
protocol or the protocol with an extended incubation with secondary antibodies
(Figure 2.7D).
As a tool for future experimentation, we attempted to purify this biomarker
utilizing various techniques to separate particles based on their properties. An
initial strategy was via ion exchange chromatography, which separates particles
based on their ionic charge. Ion exchange via DEAE resin found that IgG generally
eluted early, and potentially did not bind well to the resin, while ApoA-I was found
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to elute late in the run (Figure 2.8A). There are multiple peaks for the analyte, with
significant elution in the initial IgG peak as well as elutions mixed with ApoA-I
(Figure 2.8A). Due to the poor binding of IgG and multiple elutions of the analyte,
we attempted separations via hydrophobic interaction chromatography (HIC), a
strategy where hydrophobic properties are maximized by a high salt concentration
which is then decreased throughout the run leading to elution. HIC was performed
at a range of buffer pH values (Figure 2.8B). The elution profiles for the analyte
shift as the pH changes; however, the elution of this analyte and total IgG continue
to overlap at each pH. Based on the poor separations achieved based on chemical
properties, we pursued an alternative approach to separate particles based on
density via sucrose gradient centrifugation. Fractions collected after centrifugation
find complete overlap of IgG and analyte with no separation (Figure 2.8C). These
separation techniques failed to identify a strategy to isolate the analyte, specifically
there is significant co-elution of analyte and total IgG.
Following difficulty isolating this analyte, we sought to evaluate the ELISA to
determine if it was truly measuring ApoA-I/IgG ICs. For this purpose, we
exchanged the capture antibody utilized in this ELISA with two alternative goat IgG
antibodies, one specific for ApoB and a second antibody targeting green
fluorescent protein (GFP). We then tested the effect of this change in both human
plasma and with artificial ApoA-I/IgG ICs. Unexpectedly, the absorbance values
measured in this ELISA with human plasma were similar with all three capture
antibodies (Figure 2.9A). However, the only coating with anti-ApoA-I IgG allowed
measurement of the artificial immune complex (Figure 2.9B). These results
indicate that the biomarker measured in patients with CAD and which correlated
with future CVD events was not ApoA-I/IgG ICs, but a plasma factor which binds
to goat IgG.
2.5

Discussion

Herein, we developed an assay to measure ApoA-I/IgG ICs as a potential
biomarker for CVD progression and utilized this assay in patients from 3
populations. Importantly, use of this assay in a cohort of patients with a history of
CAD indicates that this biomarker is associated with decreased CVD events.
Subsequent analysis of samples collected from blood donors indicates that the
anti-inflammatory IgG4 subclass is enriched in this biomarker. However, continued
characterization studies indicate that the biomarker measured in this work was not
ApoA-I/IgG ICs, as intended by the ELISA design, but appears to be an interfering
factor targeting goat IgG.
The interfering factor binding to goat IgG is likely a human IgG anti-goat IgG
antibody (HAGA). Clinical assay interference can arise from a number of sources;
however, one critical form of interference in immunoassays is the presence of
interfering antibodies from patients.207, 208 These antibodies bind to assay
reagents, including non-human antibodies utilized in an ELISA, and cause either
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falsely elevated or falsely depressed values.141, 208 Importantly, these incorrect
assay results can lead to misdiagnosis and unnecessary treatment.137-139, 142, 143
Based on these previous reports of interfering antibodies in immunoassays, as well
as the use of an anti-human IgG secondary in our assay, we suspect that the
interfering factor measured in this study and identified in Figure 2.9 is HAGA.
Further evaluation will be needed to confirm this work, including competition
ELISAs to verify specificity for goat IgG and purification studies to positively identify
the binding factor as human IgG. The results of chapter 3 provide further
confirmation that the factor measured in our ELISA is HAGA.
The identification of HAGA as a biomarker which associates with decreased
CVD events is a novel discovery. Previous reports of HAGA and other human antianimal antibodies (HAAA) have focused on their role as interference agents in
assays, either in case reports or in studies evaluating the frequency of HAAA in a
larger population.144, 208-210 Additionally, several reports have sought to develop
techniques to avoid the interference by HAAA in assay to ensure accurate results
in clinical testing.211, 212 However, in this case we identify an association between
HAGA and cardiovascular events, which to our knowledge is the first such report.
Based on this determination, further evaluation of these antibodies in patients is
warranted to understand their origin and any potential mechanistic relationship with
CVD progression.
The enrichment of IgG4 within HAGA may provide a basis for the origin of
HAGA in patients. Goats and cows are phylogenetically linked species as
members of the Bovidae family. As a factor of this relationship, antibodies targeting
goat IgG will cross-react with cow IgG and vice versa.213 Additionally, antibodies
from patients, including IgG4 antibodies, are known to target proteins from cow’s
milk.214-217 Critically, while antibodies targeting cow IgG are not evaluated in these
reports, cow IgG is known to be present in cow’s milk.218 Taken together, this is a
potential indication that exposure to bovine IgG induces the expression of IgG4
targeting cow IgG which cross-reacts with goat IgG.
In summary, in this chapter we identified a novel HAGA which is associated
with decreased CVD events in patients with a history of CAD. We also identified
an enrichment of IgG4 antibodies within this novel HAGA. Notably, in subsequent
experimentation we fully identify this analyte as HAGA.
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Table 2-1 Demographics and clinical characteristics of patients with CAD.
Data

Characteristic

(n = 359)

Age, median, yr (SD)

64.2 (13.1)

Male sex, n (%)

231 (64.7)

Black race, n (SD)

84 (23.5)

Body mass index, kg/m2, median, (SD)

29.2 (5.7)

Systolic blood pressure, mmHg (SD)

138 (20)

Diastolic blood pressure, mmHg (SD)

71 (20)

Hypertension, n (%)

314 (88)

Hyperlipidemia, n (%)

274 (76.8)

Diabetes mellitus, n (%)

120 (33.6)

Obstructive CAD (>=50%), n (%)

267 (74.8)

Previous myocardial infarction, n (%)

84 (23.6)

Acute myocardial infarction, n (%)

42 (11.8)

Heart failure, n (%)

109 (30.5)

Ejection fraction, n (%)

53 (14)

Total cholesterol, mg/dL, median (SD)

158 (47)

Low density lipoprotein, mg/dL, median (SD)

92 (43)

High density lipoprotein, mg/dL, median (SD)

41 (15)

Creatinine, mg/dL, median (IQR)

1.5 (1.9)

32

Table 2-2 Spearman correlation between analyte levels and baseline
characteristics.
(n = 359) *except hs-CRP (n = 193).
Baseline Characteristic

HAGA level
Rho (P-value)

Male

0.07 (0.22)

Black

0.00 (0.98)

Age

-0.01 (0.84)

Body mass index

-0.03 (0.59)

Systolic blood pressure

-0.02 (0.75)

Diastolic blood pressure

0.03 (0.56)

Acute myocardial infarction

0.02 (0.74)

Obstructive coronary artery disease

-0.05 (0.31)

History of myocardial infarction

-0.03 (0.53)

History of heart failure

0.00 (0.95)

Diabetes

-0.09 (0.10)

Hypertension

-0.09 (0.10)

Hyperlipidemia

0.02 (0.71)

Total cholesterol

0.05 (0.32)

Triglycerides

0.00 (0.99)

High density Lipoprotein

-0.06 (0.23)

Low density lipoprotein

0.07 (0.19)

Ejection Fraction

0.07 (0.20)

Creatinine

-0.04 (0.43)

Glomerular Filtration Rate

0.08 (0.13)

*hs-CRP (N = 193)

-0.07 (0.30)
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Figure 2.1. ELISA validation assays to determine intra- and inter-assay
coefficients of variation.
Plasma samples from 16 subjects from the Kentucky Blood Center were analyzed
by ELISA in 12 coated (Black symbols) and 12 uncoated wells (red symbols) to
determine intra-assay coefficients of variation. Samples were evaluated on three
days to determine inter-assay coefficient of variation.
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Figure 2.2. Validation of linearity of the assay.
A. ELISA was completed with dilutions ranging from 1:50 to 1:400 in 12 subjects.
Subject 1 exhibited very high levels of analyte and was further diluted to 1:12,800
and is plotted on a log scale. Closed circles and solid line represent coated wells
while open circles and dotted line represent uncoated wells. B. ELISA was
completed at a constant 1:200 dilution of plasma where plasma from three high
subjects was mixed with plasma from three low subjects at ratios of 4:0, 3:1, 2:2,
1:3 and 0:4.
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Figure 2.3. Cox proportional regression analysis of patients with CAD based on
analyte levels.
A. Analyte levels were evaluated by ELISA at a plasma dilution of 1:200 in 359
patients with CAD after undergoing emergent or elective cardiac catheterization.
Absorbance values are plotted, with median denoted by line, squares are color
coded into tertiles with highest tertile in light gray, middle tertile in dark gray, and
lowest tertile in black. The mean value and 95% CI are plotted to the right. Dashed
line denotes limit of detection, defined as 5 SDs above plasma-free wells. B
Kaplan-Meier plot of major adverse cardiovascular event over a median 4.1 y
(interquartile range, 1.2–6.0 y) of follow-up in patients with CAD. Patients are
divided by analyte absorbance according to tertiles denoted in A. C. Proportional
regression models used to determine hazard ratios and CIs based on traditional
markers of cardiovascular disease. HDL indicates high-density lipoprotein; and MI,
myocardial infarction.
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Figure 2.4. Persistence of analyte in patients.
A Dot plot and B Scatter plot of analyte levels in samples collected at baseline
presentation for nSTEMI and 30 days after presentation in 58 subjects from the
TRACER study. Line in A denotes the median of each population.
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Figure 2.5. Evaluation of analyte levels in subjects from the Kentucky Blood
Center.
A. Analyte levels were evaluated at a dilution of 1:200 in 104 subjects. Absorbance
values are plotted with median denoted by black line, while on the left side the
mean is plotted with the 95% CI. B-C. Analyte levels were compared to B IgG
concentration and C ApoA-I concentration in plasma.

39

Figure 2.6. IgG subclasses in blood donor subjects.
A. IgG subclass composition in plasma of 16 blood donor subjects (8 with high
analyte levels on high binding plates and 8 with low analyte levels). B.
Concentration of IgG1 and IgG4 within plasma. C. Concentration of IgG
subclasses which contributed to the analyte for the 8 subjects with high analyte
levels. One of the 8 subjects lacked detectable IgG1 and IgG4 in the analyte and
is not plotted. For subjects where IgG1 was below the limit of detection where IgG4
was quantifiable the minimum on the IgG1 standard curve substituted. D. Ratio of
IgG1:IgG4 in plasma for 8 subjects with low analyte levels, 8 subjects with high
analyte levels and within the analyte the 7 subjects with detectable subclasses.
Testing in D utilizes Kruskal-Wallis test with Dunn’s multiple comparison. * (p <
0.05), *** (p < 0.001).
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Figure 2.7. Use of automated washer/dispenser system for analyte ELISA.
ELISA was completed with plate washer/dispenser system attached to a
microplate stacking system which presents and retrieves plates from the
washer/dispenser. A. Bar graph of absorbance values for individual patients
across the assay plates when using a 30 minute secondary antibody incubation
step. B. Bar graph of absorbance values for individual patients across the assay
plates when using a 60 minute secondary antibody incubation step. C. Dot plot of
coefficients of variation (CV) from assay plates at locations 1, 2, 6 and 10 in the
microplate stack for individual subjects. D. Scatter plot of median absorbance
values for each subject in A and B. For A and B samples were run in duplicate on
each plate, presented as average with error bars as the range. Paired T-test used
for comparison in C, **** p < 0.0001.
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Figure 2.8. Purification procedures for attempted analyte isolation.
A. ELISA measurement of analyte, IgG and ApoA-I in fractions collected from
DEAE ion exchange chromatography with increasing stepwise addition of NaCl in
buffer. B. ELISA measurement of analyte and IgG in fractions collected from
Hydrophobic Interaction Chromatography at three pH values with stepwise
decreases of (NH4)2SO4 in buffer. C. ELISA measurement of analyte and IgG in
fractions collected starting from the top of a tube after ultracentrifugation. For
visualization, the absorbance is normalized relative to the maximum and minimum
value for each factor within each assay with lines connecting individual values. For
A and B each faction was assayed in singlet, while in C each fraction is assayed
in duplicate.
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Figure 2.9. Exchange of capture antibodies in analyte ELISA.
A. Absorbance values for ELISA with three distinct goat capture antibodies utilizing
human plasma diluted 1:200. Anti-goat IgG antibody utilized as a positive control.
B. Absorbance values for the three distinct goat capture antibodies with the use 1
pmol of a 2:1 ApoA-I/IgG artificially generated immune complex. Absorbance for
wells coated with anti-ApoA-I IgG capture antibody was above the maximum value
for the instrument and is plotted as 4.0. Samples are run in duplicate with median
values and range presented.
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CHAPTER 3. IDENTIFICATION AND CHARACTERIZATION OF HUMAN ANTIGOAT IMMUNOGLOBULIN G ANTIBODIES IN BLOOD DONOR SUBJECTS
3.1

Abstract

Objective: The goal of this chapter is to characterize interfering antibodies
that bind to goat IgG, which were previously shown to be associated with
decreased cardiovascular disease events. Evaluation of these antibodies will
provide insight into the specificity for goat IgG, the potential epitopes targeted, and
the binding affinity.
Approach and Results: To confirm the interference observed in the previous
study, we evaluated the effects of three distinct goat capture antibodies as well as
capture antibodies from sheep and rabbits. Similar results with the goat capture
antibodies, as well as sheep IgG confirm our previous identification of interfering
antibodies. Decreased signal in competition ELISAs with addition of goat, sheep,
or cow IgG, but not with addition of mouse or rabbit IgG demonstrate reactivity with
IgG from phylogenetically related species. Purification and characterization using
protein G isolation, western blotting, and biolayer interferometry indicate that the
biomarker is human-IgG anti-goat-IgG antibodies (HAGA) which binds to goat-IgG
heavy chain with high affinity.
Conclusions: Interfering antibodies which are associated with decreased
rates of cardiovascular disease events are specific for goat IgG and other IgGs
from the Bovidae family, and bind to the IgG heavy chain with high affinity.
3.2

Introduction

Immunoassays provide tools to direct cardiovascular disease (CVD) care in
patients. Due to the significant morbidity and mortality resulting from CVD events,
many potential biomarkers have been tested for their ability to predict CVD
progression and direct preventative care.1, 219 These evaluations have led to the
identification of numerous CVD biomarkers which strongly correlated with CVD
events.220 Several of these biomarkers, such as apolipoprotein A-I (ApoA-I),
Apolipoprotein B (ApoB) and C-reactive protein (CRP), are quantified by utilizing
an immunoassay.45, 220, 221 Importantly, cardiac troponin, which is both a risk factor
for CVD events in patients with pre-existing CVD and a diagnostic marker of
ongoing myocardial infarction, is commonly measured during clinical care via
immunoassays.220, 222 Given the influence of these assays on clinical care they
must be specific and sensitive for their analyte of interest.
A confounding factor with any clinical assay, including immunoassays, is
assay interference from components within human samples.207 One form of
interference occurs when human antibodies, present in clinical samples, bind to
the assay reagents to enhance or suppress assay values.141, 208 Notably, case

reports demonstrate interference in troponin assays due to non-specific crosslinking antibodies, which resulted in misdiagnosis of myocardial infarction in
patients.137-139 Consequences of assay interference are not limited to diagnosis of
cardiovascular disease as interference with other clinical assays have also led to
misdiagnosis and unnecessary treatment in different patient cohorts.142, 143, 208, 210
Interfering antibodies found in patient samples are classified as human-anti-animal
antibodies (HAAA) or heterophilic antibodies (HA),141 but their presence in clinical
samples are not well studied and their induction are even less clear. Additionally,
neither HAAA nor HA have been studied for their association with disease
progression.
In this study, we characterize an interfering antibody which was found to
associate with CVD progression in patients. In chapter 2 of this dissertation, I
describe the measurement of a novel biomarker which was associated with the
rate of CVD events in patients with a history of coronary artery disease (CAD) by
using an ELISA which was designed to measure immune complexes (ICs) formed
with ApoA-I and IgG. However, subsequent experimentation indicates that the
biomarker measured in this assay was not an IC, but an interfering antibody which
binds to goat IgG. Here, we confirm the binding of this interfering antibody to goat
IgG, followed by evaluation of potential epitopes of goat IgG and studies of binding
affinity.
3.3

Material and Methods

Human samples
De-identified human blood samples are obtained from the Kentucky Blood
Center (KBC) for analysis. During the blood donation process at the KBC, EDTA
tubes are drawn, and one tube is stored at 4°C and reserved for additional testing
if needed within 7 days. Samples that were not required for additional testing were
provided to our laboratory. Upon receiving samples, plasma was separated from
the whole blood via centrifugation and stored at −80°C until assayed. A cohort of
112 plasma samples were used in this study with a subset of 15 samples used for
detailed characterization. All samples exhibit an absorbance five standard
deviation above background indicating the presence of HAGA. Nine samples were
selected with values near the top of the initial screening, three samples at the 66th
percentile and three samples with low responses. Samples sent to JPT are also
blood donor samples; however, they were not members of the 112 subject cohort
utilized throughout the paper.
ELISA Method
HAGA ELISA Streptavidin coated preblocked plates (Thermofisher, 15124)
were washed 3 times with 200 µL of phosphate buffered saline with 0.1% Tween
(PBS-T). Capture antibody was immobilized by adding 100 µL of PBS-T containing
500 fmol (72 ng) of biotinylated goat anti-ApoA-I IgG (Abcam, ab27630) to each
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well. The plates were incubated for 2 hours at 37 °C. Plates were washed 6 times
with 200 µL of PBS-T prior to the addition of 100 µL of plasma at a final dilution of
1:200 in PBS with 0.1% casein (PBS-C). Following the addition of plasma, plates
were incubated for 30 minutes at 37 °C. After incubation, plates were washed 6
times with PBS-T, then 100 µL of a 1:4000 dilution of horseradish peroxidase
(HRP) conjugated secondary antibody (goat anti-human IgG (HRP) (Abcam,
ab7153) were added to each well. Plates were incubated for 1 hour at 37 °C before
washing 6 times with 200 µL of PBS-T. The ELISA was then developed with 100
µL of room temperature tetramethylbenzidine (TMB) which incubated for 30
minutes at room temperature in the dark. The reaction was quenched with 100 µL
of 0.5M H2SO4 and resultant absorbance was measured at 450 nm (BioTek,
Synergy Hybrid Reader). Samples were run in duplicate. ELISA in Figure 1 were
washed using BioTek EL406 plate washer, all other ELISA were washed using a
multi-channel pipet.
Capture antibody Exchange Assay After initial washing plates were coated
with biotinylated polyclonal antibodies. Antibodies include: goat anti-ApoA-I IgG
(Abcam, ab27630), goat anti-ApoB IgG (Abcam, ab20898), goat anti-GFP IgG
(Abcam, ab6658), sheep anti-Cyanine IgG (Abcam, ab7625) and rabbit anti-RFP
IgG (Abcam, ab34771).
Secondary antibody Exchange After plasma incubation assay plates were
washed and incubated with HRP-Conjugated secondary antibodies. Secondary
antibodies used include: Goat anti-human IgG (HRP) (Abcam, ab7153), goat antiFluorescein IgG (HRP) (Abcam, ab6656), and Rabbit anti-human IgG (HRP)
(Abcam, ab7160).
Competition ELISA Standard ELISA procedure was utilized with
modification of plasma dilution. Free antibodies were mixed with plasma prior to
incubation with assay plates. IgG used for competition was purchased from
Rockland immunochemicals (Goat IgG 005-0102-0010, Rabbit IgG 011-01020010, Mouse IgG 010-0102-0005, Sheep IgG 013-0102-0010, Cow IgG 001-01020010) and for use in this assay is diluted to 0.72 µg/µL in PBS-C, and serially
diluted 1:50 with PBS-C. Each dilution of IgG is mixed 1:1 with a 1:100 dilution of
plasma in PBS-C. This final solution has 1:200 dilution of plasma and a ratio of
500:1, 10:1 or 0.2:1 of added IgG relative to the amount of capture IgG utilized. As
control, 1:100 dilution of plasma is also mixed 1:1 with PBS-C for a final dilution of
1:200 of human plasma and tested with or without initial coating via capture
antibody. A commercial rabbit anti-goat IgG (Abcam, ab97105) was tested along
with the human plasma samples at a final dilution of 1:20,000). Percent
interference was calculated based on the following equation:
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percent interference =

No interference − Interference sample
× 100
No interference − non specific binding

IgG Quantification ELISA High binding plates (Microlon 600) were washed
3 times with 200 µL of Na2CO3 buffer (9.7 pH, 0.05 M). Donkey anti-human IgG
(Abcam, ab102421) was diluted 1:500 in Na2CO3 buffer and added to the plates.
Plates were incubated 1 hour at 37 °C and then washed 6 times with 200 µL of
PBS-T. Plates were then blocked with 200 µL of PBS-C for 1 hour at 37 °C. The
control and IgG fraction samples were diluted to a final dilution of 1:4,000,000 while
the non-IgG fraction was adjusted to a final dilution of 1:50,000. Following a wash
with PBS-T, samples were transferred to the assay plate. Control samples with
known concentration were added to each plate to generate an 8-point standard
curve with human IgG (Genscript, A01006). Assay plates with samples were
incubated for 30 minutes at 37 °C and then washed 6 times with 200 µL of PBS-T
and a 1:4000 dilution of goat anti-human IgG (HRP) (Abcam, ab7153) was added
to each well. These plates were incubated for 1 hour at 37 °C. Plates were washed
a final 6 times with 200 µL of PBS-T and then 100 µL of room temperature TMB is
added to each plate and incubated in the dark for 30 minutes at room temperature.
The reaction was quenched with 100 µL of 0.5M H2SO4 and the resultant
absorbance was measured at 450 nm (BioTek, Synergy Hybrid Reader). Samples
were evaluated in duplicate. IgG concentration was calculated based on four
parameter regression based on the standard curve on each plate.
Protein G Spin Purification
Protein G spin columns kit (Thermofisher, 89979) was used based on
manufacturer’s instructions. Columns are centrifuged at 1000 xg for 1 minute
between washes or to collect samples. To prepare the column they were washed
2 times with 2 mL of wash buffer. Next, 2 mL of a 1:10 dilution of plasma in wash
buffer was added to the column and mixed end over end for 10 minutes at room
temperature. Flow through (non-retained fraction) was collected from the column
and saved for ELISA. The column was then washed 3 times with 2 mL of wash
buffer. To collect the bound fraction, 1 mL of elution buffer was added to the column
and collected into a new 15 mL tube with 150 µL of neutralization buffer. This
elution step was repeated 2 times with collection into the same 15 mL tube for a
final total volume of 3.15 mL. Columns were regenerated by washing with 3 mL of
elution buffer, 3 mL of wash buffer and 2 additional washes with 2 mL of wash
buffer.
During this procedure the non-IgG fraction and whole plasma controls are
diluted to 1:10 with wash buffer as a part of this procedure. For the elution, a total
of 200 µL of plasma was added to the column in the initial step and 3150 µL of
total elution volume were collected for an approximate final dilution of 1:16.
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To prepare samples for the Bio-Layer Interferometry (BLItz) assay this
procedure was repeated and the IgG fraction was concentrated via Protein
concentrator tubes with a 10k molecular weight (MW) cutoff (Thermofisher,
88516).
Western Blots
Goat IgG (Rockland Immunochemical, 005-0102-0010) was diluted to 90
µg/mL in PBS then mixed with 4x buffer containing beta-mercaptoethanol (BME)
and heated at 95 °C for 5 minutes. 4-20% mini-PROTEAN TGX Precast Protein
Gels (Biorad, 4561096) were loaded either with 6.67 µL of denatured goat IgG or
with 2.5 µL of PageRuler Plus Prestained Protein Ladder (Thermofisher, 26619) in
an alternating pattern with 7 samples and 8 ladders per gel. These gels were
electrophoresed on ice at 100 V. Transfers were completed using TurboBlot
system with Trans-Blot Turbo Mini 0.2 µm PVDF Transfer Pack (Biorad, 1704156).
Membranes were blocked with Superblock PBS (Thermofisher, 37515) overnight
at 4 °C. Membrane sections containing IgG and ladder were cut from the
membrane to stain individually with human plasma diluted 1:400 in PBS-C with
0.1% Tween (PBS-CT) for 1 hour at RT. Membranes were washed with PBS-T and
incubated with anti-human IgG secondary antibody (Abcam, ab7153) at a dilution
of 1:10,000 in PBS-CT for 1 hour at RT. Positive controls were evaluated on
membrane sections without plasma by incubating with a 1:40,000 dilution of rabbit
anti-goat IgG (Abcam, ab6741). Negative controls were evaluated by incubating
the membrane sections with PBS-CT lacking human plasma, followed by
incubation with anti-human IgG secondary antibody. Membranes were imaged
with enhanced chemiluminescence (ECL) (ThermoFisher, 32209) and (Biorad,
ChemiDoc MP). This procedure was repeated a 120 µg/mL solution of goat IgG in
PBS for samples previously identified as binding goat IgG in a western blot.
Deglycosylation of Goat IgG
Deglycosylated antibodies were prepared based on a modified protocol
from Kaneko et al.223 PNGaseF (500 units) (New England Biolabs, P0704S) was
mixed 2 mg of goat IgG and incubated at 37 °C for 41 hours. A protein G spin
column was then used to collect the IgG from the reaction mixture according to the
procedure described in the methods section. Collected IgG was compared to
untreated IgG and IgG treated with PNGaseF under denaturing conditions via
SDS-PAGE. Briefly, IgG samples were denatured in 4x loading buffer with BME
and placed in an electrophoresis chamber set at 100 V in a 10% mini-PROTEAN
TGX Precast Protein Gels (Biorad, 4561036) and stained with coomassie blue to
label proteins. The migration of heavy chain in each condition was compared to
confirm deglycosylation was complete. The IgG from each reaction condition was
then utilized in a competition ELISA at 100 times the quantity of capture antibody,
untreated goat IgG and rabbit IgG were used as controls.
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Peptide array
Samples previously identified as processing high levels of HAGA were sent
to JPT Peptide Technologies (Berlin, Germany). JPT produced PepStar peptide
microarrays using a series of 184 peptides. Peptides sequences were based on
the sequence of the three subclasses of goat IgG spanning from from the CH1
domain to the CH3 domain.224 Peptides were 15 amino acids in length with 11
amino acid overlaps between adjacent peptides, the overlapping was reset after
the hinge region for each IgG subclass, resulting in 2 peptides which each have a
14 amino acid overlap with the preceding peptide.224 Identical peptides between
the subclasses were only tested one time. A full list of peptides analyzed is
presented in Supplemental Table 3.1. The microarray was incubated with plasma
at a dilution of 1:200 for 1 hour at 30 °C. After this incubation the array was
incubated with a Alexa Fluor 647 rabbit anti-human IgG (Jackson
Immunoresearch, 109-605-098). The plate was subsequently washed, and the
fluorescence read with a 635 nm laser.
Peptides identified as potential binding epitopes were synthesized by Elim
Biopharm on resin. The peptide was subsequently labeled with biotin and prepared
for use by deprotection as described.186 Peptide was also de-protected from resin
without added biotin.
Biotinylated peptides were utilized in a direct binding assay based on the
HAGA ELISA. Briefly, streptavidin coated plates were washed 3x with PBS-T and
loaded with 100 µL of 5% DMSO in PBS-T containing either biotin anti-ApoA-I IgG
or crude biotinylated peptide 1, 2, or 4 at 0.5 µM. After this coating procedure the
ELISA was completed per the HAGA protocol.
Non-botinylated peptides were utilized in competition ELISAs based on the
competition ELISA protocol. Importantly in this procedure after 1:1 mixing of
peptide solution and 1:100 dilution of plasma the solutions were incubated for 1
hour at 37°C. This procedure was completed twice, in the first ELISA samples were
evaluated with peptide 2 and 4 at 50,000:1, 5,000:1, 500:1 and 50:1 ratios to
capture IgG, peptide 3 was evaluated as well at ratios of 50,000:1, 5,000:1 and
500:1. During the second procedure peptide solutions included DMSO to ensure
full dilution of the peptide, the final concentration of DMSO was 3.773%. This assay
was performed with peptides 1 and 4 at 50,000:1, 5,000:1, 500:1 and 50:1.
Bio-Layer Interferometry (BLItz) Assay
The BLItz instrument (Sartorius, formerly ForteBio) was used to measure
binding kinetics of HAGA. To complete the assays, the baseline interferometry for
a streptavidin biosensor (Sartorius, 18-5020) was collected in Octet Kinetics buffer
(Sartorius, 18-1105) and the sensor was then coated with biotinylated goat
antibodies at 12.5 µg/mL for 3 minutes. After the coating step, a new baseline was
established for 3 minutes in the kinetics buffer. Association between HAGA and
49

goat antibodies was then measured by incubating the probe with samples
containing HAGA for 5 minutes. Dissociation of HAGA was measured by placing
the probe in kinetics buffer for 5 min. At each concentration the samples were
evaluated with an uncoated probe, as well as a probe coated with anti-ApoA-I IgG
(Abcam, ab27630) and a probe coated with biotinylated goat anti-GFP IgG
(Abcam, ab6658). Evaluations for all four samples were completed on a single day,
then repeated on a subsequent day. BLItz Pro 1.3 software was utilized to collect
data and to determine kinetic constants. For calculation of kinetic constants, the
data for multiple concentrations with both anti-ApoA-I and anti-GFP was analyzed
without using the reference runs. Step correction was used at the start of
association and dissociation, the data was fit with the global fitting option.

Statistical Analysis
Statistical tests are completed using Graph Pad Prism 9 (Graph Pad
Software). Data was tested for normality using the Shapiro Wilk test and for
equality of variance using the Brown Forsythe test. When appropriate, based on
these results, samples were compared using Repeated Measure ANOVA with
Bonferroni’s multiple comparisons. If ANOVA was not appropriate, samples were
compared with Friedman’s test with Dunn’s multiple comparisons.
For clarity, the statistical tests used in each experiment are indicated throughout
the results section.
3.4

Results

In chapter 2, we evaluated the effect of three distinct goat IgG capture
antibodies in an ELISA originally designed to measure the level of ApoA-I/IgG ICs
and found that the absorbance values were similar with each capture antibody in
samples from a small group of blood donor subjects. To confirm this finding, we
repeated these assays in a cohort of 112 blood donors utilizing goat anti-ApoA-I
IgG, goat anti-ApoB IgG, and goat anti-GFP (green fluorescent protein) IgG
(Figure 3.1A). Linear regression analysis between goat anti-ApoA-I IgG and goat
anti-ApoB IgG found a slope of 0.97 ± 0.13 (95% CI) and a coefficient of
determination (R2) of 0.65, analysis between goat anti-ApoA-I IgG and goat antiGFP similar found a strong correlation with a slope of 1.02 ± 0.08 and an R2 of
0.89. Comparison between goat anti-ApoA-I IgG as capture antibody and an
uncoated assay plate as background results in a relatively weak correlation (slope
= 0.20 ± 0.07; R2 = 0.21) (Figure 3.1B).
Given the reactivity of the analyte for goat antibodies irrespective of capture
antibody antigen specificity, we then sought to examine the reactivity toward
antibodies derived from other species. Similar to the use of goat anti-GFP IgG, we
utilized antibodies that target fluorophores as non-native antigens for comparison,
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selecting the capture antibodies sheep anti-cyanine IgG, and biotinylated rabbit
anti-RFP (red fluorescent protein) IgG (Figure 3.1C). Sheep IgG was of particular
interest due to the similar protein sequence with goat-IgG.224 When the results of
these ELISAs are compared to results using goat anti-ApoA-I IgG, linear
regression analysis shows a correlation for both sheep anti-cyanine IgG (1.69 ±
0.18) and rabbit anti-RFP IgG (1.02 ± 0.27) with R2 of 0.75 and 0.34, respectively.
The linear regression equations and R2 from each correlation plot is shown in
Figure 3.1D.
To compare data from each capture antibody condition, the absorbance
values for the 112 plasma samples are shown using box and whisker plots in
Figure 3.1E. Statistical analysis of the comparative groups are performed with
Friedman’s test with Dunn’s multiple comparisons. The values for both the
uncoated wells and rabbit anti-RFP IgG are significantly different from each other
and the values observed when sheep- and goat-IgGs are used as capture
antibodies (p<0.0001). Although additional statistical differences are present
between sheep and goat capture antibodies, the median and 25-75 percentile
range show little variation, suggesting minimal biological difference. The difference
between median values and p value for each comparison are shown in Figure
3.1F.
To determine if the secondary antibody is responsible for the observed
results of this assay, we evaluated secondary antibodies with different antigen
specificity using 15 of the 112 subjects. The standard secondary antibody used in
this study is a horseradish peroxidase (HRP)-conjugated goat anti-human IgG
antibody, and this was compared to an (HRP)-conjugated goat anti-fluorescein
secondary antibody and a (HRP)-conjugated rabbit anti-human IgG antibody. The
mean absorbance of the anti-fluorescein secondary antibody is near background
levels (A450 = 0.08) unlike the mean absorbance value of the standard secondary
antibody (A450 = 0.52) and the rabbit secondary antibody (A450 = 0.78) (Figure
3.2A) Regression analysis indicates that signal in this assay is not driven by the
secondary antibody’s species of origin, because a strong correlation is observed
when comparing absorbances from goat and rabbit secondary antibodies (Slope
= 1.4 ± 0.17, R2 = 0.96) in contrast to a very weak correlation when comparing to
an alternative HRP-conjugated secondary antibody (Slope = 0.014 ± 0.019, R2 =
0.17) (Figure 3.2B).
To evaluate the species specificity of the analyte with the same 15 subjects,
we then performed a competition ELISA using antibodies from different species.
Competitive interference was determined utilizing commercially available IgG from
goat, mouse, rabbit, sheep and cow. (Figure 3.3A). The IgG sequence similarities
between goat, sheep, and cow antibodies provided an opportunity to compare
competition data between different species using phylogenetically similar
proteins.224 When free antibodies are incubated with sera at a 500-fold excess of
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the capture antibody utilized, interference with goat-IgG is significantly higher than
interference using mouse and rabbit IgG (p<0.0001) (Figure 3.3B). Importantly,
sheep and cow IgG exhibit similar interference to goat-IgG and are significantly
elevated over rabbit IgG interference (p<0.005) (Figure 3.3B). Statistical analysis
was performed using Friedman’s test with Dunn’s multiple comparisons. Taken
together these results indicate the biomarker of interest has affinity for goat, sheep,
and cow IgG, but not mouse or rabbit IgG.
To determine if the analyte is human IgG, protein G affinity purification was
utilized to isolate the analyte from whole plasma. IgG concentrations were
quantified in whole plasma and compared to concentrations in retained and nonretained fractions after protein G purification. As expected, IgG concentration is
reduced in the non-retained fraction as compared to whole plasma (mean of 0.35
mg/mL and 14.95 mg/mL, respectively; p<0.0001), while the retained fraction has
a mean IgG concentration of 10.83 mg/mL (p<0.0001, relative to non-retained).
IgG is also lower in the IgG fraction as compared to whole plasma (p<0.0001)
(Figure 3.4A). Statistical analysis for these measurements were performed with
repeated measure ANOVA with Bonferroni’s multiple comparisons. To measure
the analyte level in each fraction, ELISAs were completed using goat anti-ApoA-I
IgG capture antibodies. Results indicate that the analyte of interest is retained on
the protein G affinity column with a median absorbance value of 0.65, which is
similar to the absorbance of whole plasma (A450 = 0.45), while the non-retained
fraction is significantly reduced (A450 = 0.15; p<0.01 relative to whole plasma;
p<0.0001 relative to retained fraction) (Figure 3.4B). Statistical tests were
performed using Friedman’s Test with Dunn’s multiple comparisons. These results
indicate that the analyte observed in human plasma is retained on the protein G
column and is therefore human IgG anti goat-IgG antibodies (HAGA).
For preliminary characterization of HAGA we sought to explore its binding to
goat IgG by western blot. Denatured goat IgG was separated via electrophoresis
into its heavy and light chains and transferred to membranes which were
subsequently incubated with human plasma or control IgG. Blots utilizing plasma
from the 15 subjects indicate that HAGA binds exclusively to the heavy chain of
goat IgG (Figure 3.5A). For further analysis, the amount of denatured IgG in the
membrane was increased and the blotting repeated with plasma from subjects 1,
2, 3, 4, and 6. Similar to the observation in the initial blots, the IgG binds to the
heavy chain of goat IgG in this experiment (Figure 3.5B).
A potential epitope of goat IgG’s heavy chain for consideration as a binding
target of HAGA is the glycosylation in the Fc binding domain of goat IgG. Some
human and goat antibodies are marked by a sialic acid derivative as the terminal
sugar on the carbohydrate cluster.225 The specific sialic acid derivative utilized on
goat IgG is N-glycolylneuraminic acid (NGNA), which is not present in human
antibodies.225 In contrast, N-acetylneuraminic acid (NANA) is the salicylic acid
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derivative on human IgG and absent in goat antibodies.225 Therefore, we
hypothesized that dietary or environmental exposure to NGNA could serve as a
trigger to elicit an anti-goat-IgG antibody response. To test this hypothesis, we
utilized PNGaseF to cleave the carbohydrates from goat IgG (Figure 3.6A).
Interference assay with de-glycosylated IgG as well as control goat- and rabbitIgG indicate that interference is independent of glycosylation and that these
carbohydrates are not the cause of our observed interaction with HAGA (Figure
3.6B).
For evaluation of potential peptide epitopes of the goat IgG heavy chain
which may be targeted by HAGA, we worked with JPT Peptide Technologies to
complete a microarray assay. This microarray contained oligopeptides to cover the
peptide sequence of the three subclasses of goat IgG, the heatmap of binding are
demonstrated in figure 3.7A.224 Based on binding strength and correlation
between binding and previously determined HAGA, we identified three peptides
from goat IgG1 as well as an homologous peptide from IgG2 which were
synthesized by ELIM Biopharm, the location of these peptides is indicated in figure
3.7A with peptide sequences presented in figure 3.7B. These synthetic peptides
were subsequently evaluated for their ability to inhibit binding of HAGA in
competition ELISA, but competition was not observed (Figure 3.7C and D). To
replicate the binding observed in the peptide array, we also evaluated direct
binding of HAGA to these peptides utilizing plasma from the samples assayed by
JPT; however, in this evaluation there was no apparent binding to the peptides
(Figure 3.7E).
To further characterize HAGA binding, bio-layer interferometry (BLItz assay)
was utilized as an additional method to measure binding to goat-IgG in its native
form. Protein G purified IgG collected from subjects 1, 3, 5, and 15 were evaluated
at multiple dilutions relative to whole plasma. A single dilution of 1:1.31 is plotted
with comparisons between subjects and between anti-ApoA-I IgG and anti-GFP
IgG (Figure 3.8A). Importantly, the wavelength shifts between samples are similar
to the trend in ELISA absorbance, which is consistent using different capture
antibodies (Figure 3.8A). Replicate concentration dependent HAGA binding in
each plasma sample to both capture antibodies are shown in Figure 3.8B
indicating reproducible binding that align with the ELISA data. Limited sample
volume, heterogeneity in the protein G isolated fractions, and low dissociation rate
(kd) for these samples preclude accurate determination using the BLItz assay.
However, preliminary evaluation of kinetic constants generated from the
wavelength shift at multiple concentrations of IgG from subject 1 indicates that the
binding constant to goat antibodies is likely less than 10-7. These data indicate a
high affinity interaction between HAGA and goat antibodies and additional studies
are required to properly ascertain the kinetic binding data.
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3.5

Discussion

The original goal of the assay we developed was to measure ApoA-I/IgG ICs,
a potential biomarker whose identity is supported by prior literature that indicate
ApoA-I/IgG ICs are present in human146 and mouse147 samples. However, analysis
of this ELISA in a limited sample population, as described in chapter 2 of this
dissertation, indicates that binding was not directed by the antigen specificity of the
antibody, but was similar across multiple goat IgG capture antibodies. In this
chapter, we expand this experiment in a larger cohort of blood donor samples and
observe that binding is similar with three goat IgG capture antibodies, as well as
the phylogenetically linked sheep IgG. These data align with the relatively scant
number of large studies previously published on human anti-animal antibodies that
interfere with clinical immunoassays.144, 145, 208, 209 In addition, this observation is
confirmed through competition ELISA, protein G purification, western blot analysis,
and bio-layer interferometry analysis. When taken together with our previous
report, these data provide insight into an underexplored component of the immune
response that correlates with cardiovascular outcomes.
Our fortuitous observation that plasma antibodies bind to goat-IgG and are
associated with CVD outcomes provides new data to an underexplored field of
HAAA. HAAA are defined as highly specific antibodies with strong binding to their
target epitopes, and are thought to be the result of exposure to an animal derived
pharmaceutical agent or environmental exposure.208 Alternatively, heterophilic
antibodies are characterized by broad specificity and weak binding, which lead to
interference in clinical immunoassays.141 In our studies, the kinetic binding data
indicate that these antibodies are high affinity (10-7 M); however there are no
patient characteristics from this cohort or previous cohorts that indicate how
subjects might be exposed to goat-IgG to stimulate an antibody response.
Antibodies targeting proteins from cow’s milk indicates a potential
mechanism of HAGA induction. Dietary exposure to cow’s milk is known to induce
an antibody response in infants, which are heightened in those who transition from
breast milk to cow’s milk at an earlier age, but these antibodies reduce over time
due to oral tolerance.215, 216 Despite the induction of oral tolerance, Savilahta and
colleagues detected anti-cow’s milk antibodies in control populations, including
children from 7 to 14, an indication that these antibodies are not only present
transiently in infants.217 While these studies do not specifically investigate antibody
responses to cow-IgG in particular, IgG is an abundant protein in cow’s milk.218
The phylogenetic similarities between IgG from species within the Bovidae family,
including cow, may explain the high prevalence of HAGA in samples if HAGA is
shown to cross-react with cow IgG.
Competition ELISAs find incomplete interference with the addition of excess
IgG. To evaluate the specificity and cross-reactivity of HAGA we completed
competition ELISAs which showed affinity for goat IgG as well as cow IgG and
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sheep IgG. However, these antibodies were unable to fully inhibit all signal in the
ELISA, even at a 500-fold increase of added IgG to capture antibody immobilized.
While others have demonstrated 100% inhibition with bovine serum144 or purified
IgG,211 we observe 40-88% interference using our assay conditions. This
difference in competitive interference between our assay and others, may be due
to the differences between the analytes measured. Previous studies focused on
antibodies of unknown affinity that crosslink capture and detection antibodies,
while in our study we are measuring the direct binding of high affinity IgG.
The affinity of HAGA indicates that specific epitopes may be involved in their
induction with associated affinity maturation to achieve high affinity antibodies. The
structural components of IgG provide unique components to investigate antibody
reactivity, including the heavy chain, light chain, and the bound carbohydrates.102
Previous studies have demonstrated anti-goat antibodies induced in rabbits target
both the Fc and Fab portions of cow, sheep and goat antibodies,213 suggesting
that the carbohydrate portion is likely not involved as an antigenic epitope.
However, humans do not produce NGNA as a sugar and previous reports have
identified anti-NGNA antibodies in human subjects.226 Using de-glycosylated
antibodies, we confirm that NGNA is not the target of HAGA, as these deglycosylated antibodies interfere with HAGA binding to the same degree as native
goat IgG. Western blotting analysis narrows the potential epitopes as only binding
to the heavy chain is detected. Similarly, Koshida and colleagues find human antimouse antibodies (HAMA) that bind exclusively to the heavy chain of mouse
antibodies.209 Based on this observation and the indications that binding is not
driven by glycosylation we attempted to identify linear peptide epitopes via a
peptide array. While peptides are identified in the array as potential epitopes for
HAGA, the peptides failed to interfere with HAGA and showed no binding in an
ELISA. Thus, further experiments are needed to identify any epitopes targeted by
HAGA, including re-analysis of the peptide array data or an alternative epitope
study, such as mutagenesis analysis.
In conjunction with our previous study, these data describe the confirmation
and characterization of HAGA in human samples and their association with clinical
outcomes in patients. More specifically, our previous study found that elevated
levels of an analyte are associated with decreased adverse cardiovascular events
in patients with coronary artery disease (Chapter 2). In this report, we confirm the
identity of the analyte measured as HAGA. While the cohort used in this study is
de-identified and clinical data are not available, the determination that our
previously described analyte is HAGA indicate that this antibody profile is
associated with decreased disease. Furthermore, studies to elucidate the exact
cause of this antibody profile, the exact epitopes and their functional implications
in patients are warranted. While our data indicate that human antibodies target the
heavy chain of goat-IgG, this may be due to either direct exposure to homologous
antibodies through dietary consumption, therapeutic exposure or an alternative
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route. In addition, cross-reactivity may be due to other mechanisms such as
molecular mimicry or natural antibody production, and efforts to define the specific
epitopes within goat-IgG that result in this response will guide continued evaluation
of functional implications of this antibody profile.
In conclusion, antibodies targeting goat-IgG, as well as other species in the
Bovidae family, are present in human plasma and bind specifically to the denatured
heavy chain of IgG. In conjunction with our previous data, the majority of subjects
analyzed exhibit HAGA, which may interfere with immunoassay development.
Nevertheless, our findings have broad implications in clinical and biomedical
sciences and may serve as a potential biomarker for clinical diagnosis. Our results
provide clear evidence of HAGA in human subjects and highlight the need for
continued evaluation of these antibodies in relation to CVD progression.
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Figure 3.1. Effects of capture antibody used in the ApoA-I/IgG IC ELISA.
A-D. Absorbance using goat anti-ApoA-I IgG as capture antibody in comparison
to: A. Goat anti-ApoB IgG, B. Goat anti-GFP IgG, D. Sheep anti-cyanine IgG and
Rabbit anti-RFP IgG as capture antibodies and C uncoated wells. All assays are
performed with 112 plasma samples at a dilution of 1:200. E. Linear regression
analysis data from comparative ELISA assays. F. Box and whisker plot of
absorbance values from the 112 samples as shown in panels A-D, with whiskers
from 5 to 95 percentile. G. Absolute difference of median values and differences
between groups determined via the Friedman Test with Dunn’s multiple
comparison for absorbance values in F. Half-filled symbols in D and F represent
values above the maximum absorbance and reported as A450 = 4.0. Not
significant (ns), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001).
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Figure 3.2. Evaluation of secondary antibody effects in ELISA.
A. Bar graph and B. Scatter plot using goat anti-ApoA-I IgG with (HRP)-conjugated
goat anti-human IgG, (HRP)-conjugated goat anti-fluorescein and (HRP)conjugated rabbit anti-human IgG as secondary antibodies in ELISA for 15
samples with known absorbance values. A Samples evaluated in duplicate with
median and range presented.
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Figure 3.3. Interference of target analyte using control IgG competitors from
different species.
A. Fifteen plasma samples with known antibody response, as determined by
ELISA, evaluated in competition with goat-, mouse-, rabbit-, sheep- and cow-IgG.
IgG from each species was mixed with plasma prior to addition to assay plate at
different concentrations relative to capture antibody (500x, 10x, 0.2x and 0x).
Rabbit anti-goat IgG is included as a control. B. Percent interference with the
addition of 500x IgG. Samples in A are run in duplicate and presented as median
± range. Friedman’s Test with Dunn’s multiple comparisons in B.
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Figure 3.4. Antibody concentration and response to goat capture antibody after
Protein G purification.
A. IgG concentration and B. absorbance from ELISA before protein G (whole
plasma) after protein G (Non-IgG Fraction) and after elution from protein G (IgG
Fraction). n = 15. A. IgG concentration calculated from standard curve using 4
parameter regression. One way ANOVA with Bonferroni’s multiple comparisons.
Values in B are reported as median ± range. Friedman’s test with Dunn’s multiple
comparisons. ** (p<0.01), *** (p<0.001) and **** (p<0.0001).
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Figure 3.5. Identification of HAGA binding target in goat-IgG by western blot.
A. Denatured goat-IgG was probed with human plasma from the 15 subjects along
with positive controls utilizing a commercial anti-goat antibody and negative control
with no plasma additions. B. Membranes with increased goat IgG were probed
with human plasma from 5 subjects who exhibit HAGA in ELISA assays and
exhibited binding in the initial western blot. Positive control from the same
membrane was imaged separately in B. “H” denotes approximately 50 kDa the
size of the IgG heavy chain while “L” denotes approximately 25 kDa the size of
the light chain.

63

Figure 3.6. Interference with deglycosylated goat IgG.
A. Coomassie Stained gel. Lane 1, untreated goat IgG. Lane 2, control complete
PNGase reaction. Lane 3, isolated PNGase treated goat IgG. Lane 4, untreated
goat IgG. Black arrows point to heavy chain of untreated goat IgG. White arrows
to the lower molecular weight deglycosylated IgG. B. A450 values and C.
interference values for deglycosylated IgG and controls for B and C. C Friedman’s
test with Dunn’s multiple comparison. ** (p<0.01), **** (p<0.0001).
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Figure 3.7. Evaluation of peptide epitopes of goat IgG for potential HAGA
binding.
A. Synthetic oligopeptides of 15 amino acids with overlapping sequences are
evaluated on microarrays with either a plasma free control or samples containing
HAGA. Binding is measured by fluorescence with visualization as described in the
legend. Peptides identified for further analysis are indicated on the right side of the
heat map for IgG1 and IgG2. B. Peptide sequences of potential epitopes identified
in the heat map. C and D. Absorbance values from competition ELISAs utilizing
identified peptides as interfering agents. E. Absorbance values from ELISA to
measure direct binding of HAGA to peptides. Either anti-ApoA-I IgG or peptides
are immobilized on the streptavidin plate and probed with plasma from the original
subjects sent to JPT. In D interference solutions contained DMSO to ensure full
peptide solubility.
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Figure 3.8. Binding kinetics of HAGA determined by bio-layer interferometry.
A. Binding studies were completed with Protein G purified IgG fraction from four
individual subjects (1, 3, 5, and 15) spanning the range of ELISA absorbance
values. Loaded and blocked sensors were incubated with sample diluted in assay
buffer for association from 0 to 5 minutes followed by incubation with assay buffer
from 5 to 10 minutes for dissociation. Black line represents probes coated with
goat anti-ApoA-I IgG while gray lines represent probes coated with goat anti-GFP
IgG, a reference run is completed for each sample utilizing an uncoated probe
which is subtracted from the assay runs. Protein G purified IgG was diluted with
kinetics buffer to represent an approximately a 1:1.31 dilution of plasma for each
subject. B. Wavelength shift over the association step at multiple dilutions of
Protein G purified IgG for the 4 subjects in A. Data from 2 independent experiments
is presented with the median and range plotted. Samples in black are anti-ApoA-I
capture antibody, in gray are anti-GFP capture antibody.
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CHAPTER 4. ADAPTATION OF A SEROLOGICAL ASSAY FOR HIGH
THROUGHPUT MEASUREMENT OF ANTIBODIES TARGETING SARSCOV-2.
4.1

Abstract

Objective: Coronavirus disease 2019 (COVID-19) is a deadly pandemic
which has resulted in over 140 million cases and over 3 million deaths globally.
Assays to measure antibodies targeting the pathogen, Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), have been developed and in this chapter
we seek to adapt these assay for high-throughput testing in our laboratory.
Approach and results: We modified an established SARS-CoV-2 serology
assay to utilize reagents readily available in the laboratory and found that patients
with a history of COVID-19 had greater absorbance levels than COVID-19 free
subjects (p = 0.0010, T Test). We subsequently evaluated if the absorbance values
detected in this assay were consistent when using an automated microplate
washer/dispenser system to manage a set of 30 microplates. In these studies, we
observed low coefficients of variation (CV) when measuring antibodies targeting
either the Receptor Binding Domain (RBD) of the spike protein (median CV 4.8%,
interquartile range (IQR) 3.9 to 5.2) or the nucleocapsid protein (N-protein) (CV
median, 7.1% IQR 4.8-8.3). Additionally, we performed preliminary validation
studies of this assay with 7 patients with a history of SARS-CoV-2 and 35
presumed negative subjects and observed delineation of these populations by
absorbance values when measuring antibodies targeting either the RBD, the Nprotein or the full spike protein (p < 0.0001).
Conclusions: Our laboratory is able to complete measurements of SARSCoV-2 serology in a high-throughput ELISA assay with up to 30 assay plates at a
time.
4.2

Introduction

Serological evaluation of antibodies targeting Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) are prompted by limitations in the
standard testing strategy. Initial infections with SARS-CoV-2, the causative
pathogen of coronavirus disease 2019 (COVID-19), occurred in Wuhan, China in
late 2019. Global spread of this virus led to the declaration of a pandemic in March
2020 and as of April 2021 there have been over 140 million cases of COVID-19
and more than 3 million dealths.227-229 While polymerase chain reaction (PCR)
testing to measure viral nucleic acids has been the gold standard test for the
diagnosis of COVID-19 throughout the pandemic, the frequency of testing was
inadequate in the early stage of the pandemic due to reagent shortages.230-232
Additionally, PCR testing has limited use as a diagnostic test for COVID-19 in
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patients after initial infection because PCR positivity decrease in patients over
time.233 Based on these limitations, there was a desire to develop an alternative
assay to identify patients who may have been infected with SARS-CoV-2 but not
diagnosed via PCR testing. To fill this gap, researchers evaluated the antibody
response in patients with a known diagnosis of COVID-19 and found these patients
exhibited increased antibodies targeting antigens of SARS-CoV-2, including the
spike protein; the receptor binding domain (RBD), a subunit of the spike protein;
and the nucleocapsid protein (N-protein).155, 156 These studies support the use of
serological testing to determine ongoing or previous SARS-CoV-2 infection.
Beyond the identification of previously undetected infections, serology may
identify patients with a protective antibody response. In a previous outbreak of a
related virus, SARS-CoV, neutralizing antibodies were detected in many patients
after infection.152, 153 Early in the COVID-19 pandemic it was unclear if patients
developed neutralizing antibodies to SARS-CoV-2 after infection; however,
subsequent evaluations indicate that neutralizing antibodies are present in patients
and correlate with the overall antibody response detected in serological studies.162164
These results prompt further evaluation of antibodies targeting SARS-CoV-2 as
seropositivity may indicate protection from subsequent COVID-19 in patients.234
In this chapter, we demonstrate the potential of our laboratory to complete a
high-throughput serology assay to measure antibodies targeting antigens from
SARS-CoV-2 in patient samples. In chapter 2 of this dissertation, I describe the
use of an automated plate washing and dispensing system to aid in the evaluation
of HAGA in patients. Here we apply our experience with this system to the SARSCoV-2 serology studies to enable the measurement of up to 1200 samples at a
time.
4.3

Methods

Human Samples
During the blood donation process at the Kentucky Blood Center, blood is
collected into tubes containing EDTA and stored at 4 °C for 7 days. Additional
samples are stored as a reserve for potential additional testing and provided to our
laboratory when additional testing is unnecessary by the Kentucky Blood Center.
Upon receiving samples, plasma was separated from the whole blood via
centrifugation and stored at −80 °C until assayed. Samples are de-identified and
lack associated demographic and clinical data. Samples collected by the Kentucky
Blood Center and used in this chapter were delivered to our laboratory by 2/6/20
and were presumed negative for SARS-CoV-2 infection, as the first confirmed case
of SARS-CoV-2 was reported in Kentucky in March 2020.235
Samples from patients with a history of SARS-CoV-2 infections or controls
were collected at the University of Kentucky by the Center for Clinical and
Translational Sciences or at the University of California San Francisco. These
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samples are provided to our laboratory de-identified, and no demographics or
clinical data is available beyond their history of SARS-CoV-2 infection.
All samples were heat-inactivated at 56 °C in a water bath for one hour to
inactivate any infectious SARS-CoV-2 virus in the samples.
ELISA procedure for anti-SARS-CoV-2 ELISA
The procedure to analyze SARS-CoV-2 was developed based on a
previous report with minor modifications.236 High-binding plates (Microlon 600)
were coated with 50 µL of antigen diluted to 2 µg/mL in PBS overnight at 4 °C
covered with a plastic film. The plates were then washed 3 times with of PBS
containing 0.1% Tween (PBS-T) and blocked with 200 µL of PBS-T containing 3%
skim milk powder for at least 1 hour at RT. Blocking buffer was removed and 100
µL of human samples diluted with PBS-T containing 1% skim milk powder was
added to each well and incubated for 2 hours at RT. The plates were washed 3
times with PBS-T and incubated with 50 µL of (HRP)-conjugated anti-human IgG
(Abcam, ab7153) in PBS-T containing 1% skim milk powder. After a 1 hour
incubation at RT, the plates were washed a final 3 times prior to addition of TMB
warmed to room temperature (RT). A final incubation for 30 minutes in the dark
was completed prior to addition of 0.5 M H2SO4 and measurement of absorbance
values at 450 nm. Table 4-1 indicates variation in conditions between individual
assays reported here.
Plate Washer
An EL-406 Plate Washer Dispenser (Biotek) attached to a syringe pump
and an automated plate stacking system (Biostack 3, Biotek) was used to aid in
the processing of ELISAs. For the evaluation of the set of 30 total microplates, a
mixture of assay plates and non-assay plates were used with the location of the
assay plates indicated with the associated data. During wash steps all plates were
washed identically. For the room temperature incubations within the ELISA
procedure, assay plates and non-assay plates are retained within the plate stack.
To resemble the conditions of an ELISA with assay plates at every position,
reagent or dilution buffer was added to non-assay plates within the stack, either to
all non-assay plates or to non-assay plates which immediately proceed or follow
an assay plate. For the initial coating step only assay plates were coated and these
plates were stored at 4 °C covered by a plate-sealing film.
Statistics
Graph Pad Prism 9 was utilized for graphing and hypothesis testing. Normality
was assessed with the Shapiro-Wilks test, and appropriate testing was completed
either with T-test or via the Mann-Whitney for non-parametric testing. Coefficient
of variation (CV) was determined in Excel by dividing the standard deviation of
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absorbance A450 values for all wells from a single subject by the average
absorbance for that subject.
4.4

Results

Given our familiarity with the automated plate washer dispenser prior to the
COVID-19 pandemic, our laboratory sought to determine if we could detect
antibodies binding to SARS-CoV-2 antigens as an indicator of previous infection.
For this purpose, we began with an ELISA procedure developed by the Krammer
lab and modified it to use reagents which were readily available in our laboratory,
as this would facilitate our rapid deployment of this assay.236 These substitutions
included the use of alternative high-binding plates and secondary antibodies as
well as the use of TMB as the development reagent in place of OPT (ophenylenediamine dihydrochloride).
Initially, we evaluated if this modified procedure could differentiate between
patients with or without a history of COVID-19 by measuring antibodies targeting
the RBD (Figure 4.1A). The result of this initial ELISA indicates anti-RBD IgG is
elevated in patients with a history of COVID-19 in comparison to COVID-19 free
subjects (p = 0.0010, T-test). Based on the success of this assay and a desire to
screen as many subjects as possible, we tested if the procedure would be
reproducible when utilizing the washer dispenser system in conjunction with the
automated plate stacking system to process a set of up to 30 assay plates. For this
evaluation we utilized assay plates at positions 5, 10, 15, 20, 25 and 30 within the
stack, an assay plate was originally present at position 1; however, an error was
made during the procedure and this plate was excluded from analysis (Figure
4.1B). Importantly, the results of this evaluation indicate the assay is reproducible
across a set of 30 plate as the CV is low (median CV 4.8%, interquartile range
(IQR) 3.9 to 5.2).
We next evaluated if similar consistency would be observed with an
alternative antigen, the N-protein. Due to limited sample volumes, we utilized a
pooled sample created from 5 subjects with a history of COVID-19, as well as
presumed negative controls from the blood center to evaluate reproducibility of the
anti-N protein ELISA over a stack of up to 30 plates with assay plates at position
1, 10, 20, and 30 (Figure 4.1D). Similar to the results obtained using RBD as
analyte, low variability is observed (CV median 7.1%, IQR 4.8-8.3) (Figure 4.1D
and E).
Pilot validation finds SARS-CoV-2 ELISAs identify patients with a known
history of infection. To determine if our in-house ELISA can differentiate between
positive and negative samples, we evaluated the validity with three SARS-CoV-2
antigens, RBD and N protein which both have been tested in 30 plate stacks, and
the full Spike protein, from which RBD is a subunit. In this assay we utilized
samples from 7 patients with a history of COVID-19 and 35 presumed negatives
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collected before March 2020 (Figure 4.2A – C). The dotted line in these figures
represents three standard deviations above the average value of the presumed
negatives, a threshold which divides the positive samples from the presumed
negative values. Importantly, the results of this ELISA indicate that antibodies
targeting SARS-CoV-2 antigens are elevated in subjects with a history of COVID19 in comparison to the presumed negative subjects (p < 0.0001) While repeated
assays in a large sample size would be required to fully establish this ELISA for
use, this pilot study indicates the potential of this assay.
4.5

Discussion

In this chapter, we indicate the potential of our laboratory to do highthroughput testing for SARS-CoV-2 serology. Initially, we adapted a procedure for
measurement of these antibodies to utilize reagents present in our laboratory.
Subsequently, we evaluated these assays for use on an automated plate washing
and dispensing system and found that assays measuring antibodies targeting RBD
and the N-protein were consistent across a set of 30 microplates. Additionally, we
performed preliminary validation utilizing 7 samples with a history of COVID-19
and 35 presumed negative samples and observed partitioning between these two
populations. In combination, these data indicate that our laboratory has the
potential to complete high-throughput screening to identify patients with a history
of SARS-CoV-2 infection.
An important role of serology studies is to identify previously undiagnosed
COVID-19. PCR screening studies find that many subjects will become infected
with SARS-CoV-2 but experience no symptoms.237, 238 This indicates that in the
absence of regular testing of total populations, a portion of SARS-CoV-2 infected
patients will go undiagnosed leading to an undercount of total infections.
Therefore, serological testing may play a role in the assessment of the total
frequency of infections. A meta-analysis of such studies focused on the effect of
the first wave of COVID-19 infections globally found that while approximately 21
million confirmed cases had been reported by mid-August of 2020, the true case
count might have been closer to 260 million infections by this timepoint.157, 158 The
ability of our laboratory to conduct similar testing could enable an evaluation of
seroprevalence in our region aided by established relationships with pharmacies
which are embedded within local communities.239
Determination of serology status may indicate risk of future COVID-19
infection. An indication of a protective antibody response is found in the correlation
between the response in the serology studies and the titer of neutralizing
antibodies as mentioned in the introduction.162-164 Additionally, several prospective
studies find incident SARS-CoV-2 positivity as determined by PCR is decreased
in subjects which exhibit seropositivity at baseline.159-161 These reports indicate
that a protective humoral immune response is developed in patients after SARSCoV-2 infection, which can be measured by serological assays, therefore,
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evaluation of seropositivity may indicate the risk of future waves of COVID-19
infections in a population.
Specific serology determinations may delineate vaccinated patients from
previously infected patients. As vaccinations expand seropositivity will increase as
the currently approved vaccines have all been shown to induce an antibody
response in patients.240-242 Importantly, the major antigen target of each of these
vaccines is within spike protein, while no currently approved vaccine is directed at
the N-protein.240-243 Based on this vaccine design, presence of anti-N-protein
antibodies may be indicative of a SARS-CoV-2 infection while seropositivity
directed towards the spike and subunits without an N-protein response may
suggest vaccination.
The low variability across plates in the SARS-CoV-2 ELISAs indicate a
potential improvement of the HAGA ELISA procedure. Similar to the design of
numerous ELISA in our laboratory, the original HAGA ELISA was developed with
several incubations at 37 °C, including incubations with diluted plasma and
secondary antibody. In contrast, the SARS-CoV-2 ELISA procedure completes
these steps by incubating at RT. Evaluation of variability indicates that these RT
incubations have a potentially beneficial effect as CV values are low within the
SARS-CoV-2 ELISAs with stacks of up to 30 plates. Additionally, completion of
incubations at RT reduces number of times plates will be stacked, unstacked and
otherwise manipulated, potentially reducing the inherent risk of human error which
is present any time the plates are manipulated. Given these potential benefits, the
HAGA ELISA should be attempted with RT incubation steps to determine if such
incubations should be incorporated into the assay.
In conclusion, within this chapter we indicate that our laboratory is able to
complete ELISAs to measure antibodies targeting SARS-CoV-2 in a highthroughput manner. Based on the results of previous studies which indicate that
seropositivity can identify patients with a history of COVID-19 and at a lower risk
of future SARS-CoV-2 infection, the results of serological evaluations in the local
community may provide a greater understanding of the historic prevalence of
SARS-CoV-2 and risk of future COVID-19 disease in the population.
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Table 4-1 Conditions of serological studies to measure antibodies targeting SARSCoV-2.
Figure

4.1 A

4.1 B

4.1 D

4.2 A

4.2 B

4.2 C

Antigen

RBD

RBD

N-Protein

RBD

N-Protein

Spike

Sample dilution

1:200

1:200

1:50

1:50

1:50

1:50

Sample
incubation

2 hours

2 hours

2 hours

2:20

2:20

2:20

Secondary
dilution

1:4000

1:4000

1:50,000

1:50,000 1:50,000

1:50,000

Secondary
incubation

1 hour

1 hour

1 hour

1:05

1:05
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1:05

Figure 4.1. High throughput serological study of antibodies targeting SARS-CoV2.
A. Bar chart of absorbance values from assay to detect anti-RBD IgG in subjects
with history of COVID-19 or without a history of COVID-19. B. Bar chart of
absorbance values of anti-RBD IgG ELISA across a 30 microplate stack utilizing
the same subjects as A. C. Bar chart of coefficient of variation for anti-RBD ELISA
depicted in B. D. Bar chart of absorbance values of anti-N protein IgG ELISA
across a 30 microplate stack with either pooled samples from subjects with a
history of Covid-19 or presumed negative blood donors. E. Bar chart of coefficient
of variation for anti-N protein ELISA depicted in D. Samples on each assay plate
are run in duplicate and presented as the average value with error bar depicting
the range except for the pooled plasma sample from patients with a history of
COVID-19 which was run in quadruplicate. Comparison in A is via a T-test **, p <
0.01.
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Figure 4.2. Preliminary validation of serological study evaluating antibodies
targeting SARS-CoV-2.
A-C. Dot plots of ELISA to detect IgG antibodies targeting (A) RBD, (D) N protein,
and (C) Spike in subjects with history of COVID-19 or presumed negatives. The
dotted line in each graph is 3 standard deviations above the average value for the
presumed negative samples. Comparisons via Mann-Whitney Test ****, p <
0.0001.
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CHAPTER 5. EVALUATION OF DOXORUBICIN LIPOSOMES IN
SUPPRESSION OF AN EPITOPE-SPECIFIC IMMUNE RESPONSE
5.1

THE

Abstract

Objective: Certain autoimmune diseases are caused by B cells production of
autoantibodies targeting known autoantigens. Despite an understanding of the
epitopes targeted by these pathologic autoantibodies, treatment is focused on total
immunosuppression. Based on previous reports of epitope-specific
immunomodulation, we propose to utilize doxorubicin liposomes to induce epitopespecific suppression of a preexisting immune response.
Approach and results: The effect of doxorubicin liposomes is initially
evaluated in mice with a preexisting immune response to a model carbohydrate
antigen. In this study epitope specific IgG was measured after suppression and reimmunization, the resulting absorbance values indicate that doxorubicin
liposomes, with or without labeling by the carbohydrate, suppress the antibody
response. To determine if this effect was due to changes in the peritoneal cavity
after doxorubicin liposomal dosage, we analyzed the cells of this cavity via flow
cytometry. Flow cytometry indicates that CD19+ cells and F4/80High cells trend
lower in mice given doxorubicin liposomes with or without carbohydrate.
Additionally, analysis of the forward scatter and side scatter plots indicate a
potential new cell population after suppression. For analysis of suppression
outside the peritoneal cavity, a dual immunization experiment was completed by
adding a peptide antigen that is given via subcutaneous immunization to the
model. Regardless of low absorbance values in all mice given doxorubicin
liposomes labeled with peptide, the results of this study are ambiguous due to
variation in the re-immunization response amongst the control mice.
Conclusions: While additional studies are needed to develop an ideal
immunosuppressive strategy with doxorubicin liposomes, the results of this study
support the potential of this strategy and can direct the design of future
experimentation.
5.2

Introduction

Autoimmune diseases occur when tolerance is broken and the immune
system targets autoantigens.244 The immune response to these autoantigens can
be very specific due to the contribution of lymphocytes, specifically T and B cells
which express an extracellular receptor unique to individual cells that binds
specifically to a target.173, 245, 246 Binding of this receptor can lead to activation of
the cell’s effector functions. For B cells specifically, activation leads to the
production of a secreted version of the B cell receptor called an antibody;
internalization and processing of the bound antigen for presentation to other
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immune cells; clonal expansion, increasing the quantity of epitope-specific B cells;
and mutations of the BCR leading to a higher affinity interaction in a process called
affinity maturation.94 These effector functions, driven by an interaction with a
specific autoantigen, can cause harm in patients and trigger a feedback loop
increasing inflammation and recruiting other immune cells for activation.247
Despite identification of specific epitopes in certain autoimmune diseases,
approved treatments focus on non-specific therapy. In Goodpasture’s Disease and
Pemphigus Vulgaris the target of the pathogenic autoantibodies has been
identified; however, the treatments for these diseases rely on broad
immunosuppressive agents such as corticosteroids.171, 173, 176, 178 Importantly, there
are no current treatments which focus on specifically eliminating the lymphocytes
targeting the autoantigen and causing disease. To fill this gap, the Payne group
has completed pre-clinical work in Pemphigus Vulgaris utilizing a cell based
therapeutic to eliminate epitope-specific B cells in an animal model.248, 249 Mice
receiving this treatment exhibit decreased levels of antibodies targeting
Desmoglein 3 and experience decreased blistering, connecting elimination of
specific B cells with decreased effector antibodies and clinical improvement.248, 249
While this treatment is not yet approved for patients, it indicates that epitopespecific modulation of antibody responses in autoimmunity is possible.
An alternative immunomodulation strategy, which has been tested in animal
models, is the use of liposomes containing the drug doxorubicin. Initial evaluation
of liposomal doxorubicin focused on inhibition of a primary immune response, Oja
et al. found that injection of doxorubicin liposomes labeled with ovalbumin inhibited
an immune response to ovalbumin in an epitope-specific manner.169 Additionally,
while injection of liposomes stabilized with polyethylene glycol (PEG) induce an
anti-PEG IgM response, this response is muted in animals given PEGylated
liposomes containing doxorubicin.167 Beyond these studies evaluating the
blockade of a novel immune response, a study evaluated the ability of doxorubicin
liposomes to suppress a preexisting allergic response to ovalbumin and found
partial suppression of anti-ovalbumin IgE in this model.170 Importantly, they also
found co-localization of fluorescently labeled ovalbumin liposomes and B cells in
mice with a preexisting immune response to ovalbumin. This indicates that
epitope-specific B cells may internalize epitope labeled liposomes, indicating a
potential mechanism as this process would lead epitope-specific B cells
internalizing any pharmaceutical agent contained in a liposome.170
In this study, we proposed to explore the role of liposomal doxorubicin in
preexisting antibody responses based on the framework described above. We
induce an antibody response with initial injections of immunostimulatory liposomes
labeled with a model antigen. After the establishment of an antibody response, we
inject labeled doxorubicin liposomes to suppress the response. These mice are
subsequently reimmunized with immunostimulatory liposomes and the response
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to this boosting immunization is used to determine if the doxorubicin liposomes
induced suppression. While further experiments are needed to establish a final
protocol, our work supports the potential of doxorubicin liposomes as a platform
for immunosuppression.
5.3

Methods

Mice
Six-week-old female Balb/C mice (stock Balb/cJ) were purchased from The
Jackson Laboratory (Bar Harbor, ME) and housed in a pathogen-free facility at the
University of Kentucky. Mice were sedated with isoflurane for blood collection and
injections. Blood was collected via the superficial temporal vein puncture using a
small animal lancet. After clotting, the serum was collected and stored at -80 °C
until use. Mice were fed ab-libitum with Teklad no. 2918 a standard chow diet. All
procedures were approved by the University of Kentucky Institutional Animal Care
and Use Committee.
Liposomal preparation
This study utilized two distinct lipid conjugated immunogens, the
carbohydrate antigen of blood group A from humans, which was a part of a
functional spacer lipid construct (FSL-A), and a peptide from mouse apolipoprotein
A-I, which spans the lecithin:cholesterol acyltransferase (LCAT) binding region
(ApoA-I141-184), conjugated to cholesterol hemisuccinate (CHEMS) (Elim
Biopharm). CHEMS-ApoA-I141-184 has been previously utilized in our laboratory
and has been shown to generate an antibody response after immunization.186
FSL-A immunostimulatory liposomes were formulated by mixing 1,2-dimyristoylsn-glycero-3-phosphocholine (DMPC) (Avanti, 850345); 1,2-dimyristoyl-snglycero-3-phospho-(1'-rac-glycerol) (sodium salt) (DMPG) (Avanti, 840445);
Cholesterol (Alfa Aesar, A11470); FSL-A (Kode Materials, 421604); and MPL-A
(Sigma, L6638) at either a 15:2:3:0.5:0.3 ratio for a full MPL-A formulation or
15:2:3:0.5:0.15 ratio for a half MPL-A formulation. ApoA-I peptide liposomes were
formulated by mixing DMPC, DMPG, Cholesterol, and MPL-A at a ratio of
15:2:3:0.15 and adding CHEMS-ApoA-I141-184. These mixtures were then dried
down to form a thin lipid film and rehydrated to 20 mM in PBS. For the ApoA-I
liposomes, the final concentration of CHEMS-ApoA-I is 1 mg/mL. The rehydrated
liposomes were then extruded with a 100 nm filter.
For suppression liposomes, a control liposomal formulation was prepared
containing a 55:45 ratio of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
(Avanti, 850365) and cholesterol. For FSL-A suppression, the DSPC and
cholesterol solution was mixed with 0.9% FSL-A and for ApoA-I suppression the
DSPC and cholesterol solutions was mixed with CHEMS-ApoA-I141-184 peptide.
The peptide was added such that at a solution of 5 mM of rehydrated liposomes
would contain 0.25 mg/mL of CHEMS-ApoA-I141-184. These solutions were dried to
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a thin lipid film and remote loaded with doxorubicin. Briefly, the lipid was rehydrated
with 300 mM ammonium sulfate and extruded with a 100 nm filter. These
liposomes were then buffer exchanged to 0.9% saline with a PD-10 column
(Cytiva, formerly GE healthcare, 17-0851-01) and the collected liposomes were
mixed with a 2 mg/mL solution of doxorubicin in 0.9% saline where the ratio of lipid
to doxorubicin was 1:0.2. The mixture of liposomes and doxorubicin were then
heated in an oven at 70 °C. After doxorubicin loading, the liposomes were
separated on a PD-10 column with 0.9% saline. Concentration of doxorubicin was
determined by absorbance in liposomes lysed with triton x100. Unlabeled
doxorubicin-free liposomes were produced along with the doxorubicin
formulations, but saline was added in place of a doxorubicin solution prior to
heating of these samples in the 70 °C oven.
Labeled fluorescent liposomes were formulated by mixing 1,2-dipalmitoylsn-glycero-3-phosphocholine (DPPC) (Avanti, 850355); cholesterol; and 1,1'Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate
Salt (DiD) (Thermofisher, D7757) at a ratio of 66:33:0.5 and adding FSL-A at 20
mol% of total lipid. The lipid was dried down to a thin lipid film and rehydrated in
PBS at 2.5 mM.
Animal experiments
Seven-week-old mice were immunized with immunostimulatory liposomes.
Mice either received 50 µL of full MPL-A FSL-A liposomes via intraperitoneal
immunization or 50 µL of half MPL-A liposomes via intraperitoneal injection and 50
µL of CHEMS-ApoA-I141-184 liposomes via subcutaneous injection. After 14 days,
mice were given either control or suppression formulations via intraperitoneal
injection. Mice given full MPL-A FSL-A immunization received either drug free
liposomes, unlabeled doxorubicin liposomes, or FSL-A labeled doxorubicin
liposomes. Mice which were given both FSL-A and ApoA-I peptide immunization
received either drug free liposomes, FSL-A labeled doxorubicin liposomes or
CHEMS-ApoA-I labeled doxorubicin liposomes. The doxorubicin dose in this study
was 160 µg per mouse. Fourteen days after this injection mice were given a
booster immunization matching their immunization at Day 0. Blood was collected
at day 0, day 7, and day 35. A cohort of naïve mice were bled along with the
experimental mice but received no liposomal injections. At day 21, 7 days after
suppression, mice treated with the protocol described above were terminated for
flow cytometry.
ELISA
For the anti-FSL-A IgG ELISA, FSL-A was diluted with ethanol to 50 µg/mL
and 50 µL per well added to a 96 well plate (Greiner Bio-One, 655101). The plate
was then left uncovered overnight to allow the solvent to evaporate. The next day,
the plate was blocked with 200 µL of PBS containing 0.1% of casein (PBS-C) for
80

2 hours at 37 °C. After 6 washes with 200 µL of PBS containing 0.1% tween (PBST), 100 µL of mouse serum diluted 1:200 with PBS-C was added to the plates and
the plates were incubated for 30 minutes at 37 °C. The plates were then washed
6 times with PBS-T and 100 µL of anti-mouse IgG HRP diluted 1:2000 with PBSC was added to the plate prior to incubation for 30 minutes at 37 °C. After a final 6
washes, 100 µL of room temperature tetramethylbenzidine (TMB) was added to
the plates and incubated in the dark for 30 minutes. The reaction was quenched
with 0.5 M sulfuric acid and absorbance at 450 nm (A450) was determined via Biotek
synergy plate reader.
To measure Anti-ApoA-I141-184 IgG, streptavidin plates were washed 3 times
with 200 µL of PBS-T and biotinylated peptide prepared as previously described
was dissolved in PBS-T and added to the plate.186 This was incubated for 2 hours
at 37 °C. The plate was then washed 6 times with PBS-T prior to addition of 100
µL of serum diluted 1:200 in PBS-C. The remaining protocol mirrors that of the
anti-FSL-A IgG ELISA described above.
Flow cytometry
Mice for flow cytometry were sacrificed with CO2 7 days after suppression.
Peritoneal lavage250 was then completed by exposing the peritoneal membrane
via dissection and injecting PBS containing 3% fetal bovine serum (FBS) (Gemini,
100-106) into the cavity. This fluid was collected and the procedure repeated.
Peritoneal lavage fluid was stored on ice until it was centrifuged to collect cells.
The cells were treated with ACK (Ammonium Chloride Potassium) lysis buffer to
lyse any red blood cells and counted (Biorad TC20). After counting, cells were
aliquoted into tubes of 500,000 live cells. The cells were suspended in flow buffer
and treated with TruStain FcX (Biolegend, 101320) followed by a 1:800 dilution of
anti-CD19 PE/Cy7 (Abcam, 210210) and 0.25 ug per tube of anti-F4/80 PE
(eBioscience, Invitrogen, 12-4801-82) for 40 minutes at 4 °C. The samples were
then washed 2 times with flow buffer. Following a final wash with PBS, the cells
were treated with a 1:2000 dilution of 2.5 mM FSL-A fluorescent liposomes for 40
minutes at 4 °C. Cells were washed 3 times with PBS then analyzed by flow
cytometry on an AttuneNxt (Thermo).
Statistical analysis
Analysis of flow cytometry data were completed in Flow Jo Version 10.
Statistical analysis and plotting was completed using GraphPad 9. Normality was
evaluated via Shapiro-Wilks test and equality of variance via the Brown-Forsythe
test. When appropriate, comparisons between groups were made via ANOVA with
Bonferroni’s multiple comparisons test. For non-parametric testing we utilized
Kruskal-Wallis with Dunn’s multiple comparison.
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5.4

Results

To build on previous reports of immunomodulation with doxorubicin
liposomes, we evaluated the effect of these liposomes in a preexisting immune
response to a carbohydrate antigen. For this study we selected a clinically relevant
model carbohydrate antigen, the blood group A carbohydrate, which was
formulated into liposomes for evaluation on the timeline displayed in Figure 5.1A.
Serum collected 7 days after initial immunization demonstrates that
immunostimulatory FSL-A liposomes induce an anti-FSL-A IgG response in mice
(range 0.068-0.086, n = 3, for unimmunized mice, 0.14-0.95, n = 15, for immunized
mice) (Figure 5.1B). With this immune response established, mice were then
given either drug free liposomes, unlabeled doxorubicin liposomes, or FSL-A
labeled doxorubicin liposomes at day 14, followed by a booster immunization at
day 28. Absorbance values in mice after the booster immunization indicates that
treatment with either unlabeled doxorubicin liposomes (mean A450 = 0.87, n = 5) or
FSL-A labeled doxorubicin liposomes (mean A450 0.72, n = 5) suppress the antiFSL-A IgG response in comparison to the drug free liposomes (mean A450 = 2.7, n
= 5) (p < 0.05, ANOVA with Bonferroni’s multiple comparisons) (Figure 5.1B and
C). These results indicate an epitope-independent effect of doxorubicin liposomes
in this model. We hypothesized this may occur due to general changes in the cells
of the peritoneal cavity in response to the injected doxorubicin liposome.
Importantly, this cavity is the site of both immunization and suppression in this
model.
To evaluate the impact of liposomal doxorubicin in the peritoneal cavity,
cells were collected via peritoneal lavage. These cells were stained with anti-F4/80
antibodies to identify monocytes and macrophages and anti-CD19 antibodies to
identify B cells prior to assessment in the flow cytometer (Figure 5.2A).
Fluorescent liposome labeled with FSL-A were also included in the flow cytometry
staining; however, in this study they failed to label B cells in immunized mice
(Figure 5.2B and C). One indication that doxorubicin induces a change in the
peritoneal cavity is the emergence of a pronounced cell population in the forward
and side scatter plots of mice treated with doxorubicin liposomes with or without
FSL-A (Figure 5.2D and E). Identification of this population is inconclusive due to
the limited panel of antibodies, but this new cell population does not appear to be
CD19+ or F4/80High (Figure 2.2F). Evaluation of total cells within the peritoneal
cavity indicate that the percentage of CD19+ cells and F4/80High cells trend down
in mice treated with doxorubicin (Figure 2.2G and H). These results together
indicate a broad and non-specific effect of liposomal doxorubicin in the peritoneal
cavity.
To examine the effect of liposomal doxorubicin on epitope-specific antibody
responses outside of the peritoneal cavity, we utilized a double immunization
model. Mice received subcutaneous immunization of immunostimulatory
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liposomes containing the lipid conjugated peptide CHEMS-ApoA-I141-184 as well as
an FSL-A immunization given intraperitoneally, the timeline of immunization is the
same as shown in figure 5.1A. The priming immunizations induce antibody
responses to both FSL-A (A450 range 0.068-0.086, n = 3, for unimmunized mice,
0.16-1.6, n = 15, for immunized mice) and ApoA-I141-184 (A450 range 0.094-0.12, n
= 3, for unimmunized mice, 0.21-0.79, n = 15, for immunized mice) (Figure 5.3A
and B). Immunized mice were subsequently injected at day 14 with either drugfree liposomes, FSL-A labeled doxorubicin liposomes, or ApoA-I141-184 labeled
doxorubicin liposomes, followed by boosting immunizations at day 28. The antiFSL-A IgG response after booster immunization shows a similar pattern to Figure
5.1C, absorbance value in mice given doxorubicin liposome with FSL-A labeling
(median A450 of 0.30, n = 5) or ApoA-I peptide labeling (median A450 of 0.87 n = 5)
trend lower than in mice given drug free liposomes (median A450 greater than 4 n
= 5) (Figure 5.3A and C). The only significant difference detected in these
comparisons is between mice given FSL-A labeled doxorubicin liposomes and
mice given drug free liposomes (p < 0.01, Kruskal-Wallis with Dunn’s multiple
comparisons). The response to the ApoA-I peptide booster immunization was
inconsistent within the non-suppressed and FSL-A suppressed groups, while all
mice in the ApoA-I peptide suppressed group have a low antibody response at day
35 (Figure 5.3B and D). Comparison between groups indicate that absorbance
values trend lower in mice treated with ApoA-I141-184 labeled doxorubicin liposomes
(median A450 of 0.29) as compared to non-suppressed mice (median A450 of 0.49)
and mice treated with FSL-A labeled doxorubicin liposomes (median A450 of 0.58)
with the only detected significant difference between ApoA-I141-184 suppression and
FSL-A Suppression (p < 0.05, Kruskal-Wallis with Dunn’s multiple comparison).
5.5

Discussion

In this study we evaluated the utility of doxorubicin liposomes as an epitopespecific suppression strategy for a preexisting immune response in mice. The
results indicate that intraperitoneal injection of doxorubicin liposomes induces an
epitope-independent change in the antibody response to a carbohydrate antigen.
To determine if doxorubicin liposomes caused local changes in the peritoneal
cavity, potentially inducing the epitope-independent effects, cells from the
peritoneal cavity were analyzed via flow cytometry. This analysis revealed potential
changes in the scatter profile and a trend towards decreased levels of CD19+ and
F4/80High cells in mice treated with doxorubicin liposomes. A double immunization
experiment was also completed to evaluate modulation of immune responses to a
peptide immunogen given subcutaneously in addition to the carbohydrate antigen
given intraperitoneally. Mice given doxorubicin liposomes labeled with the peptide
all exhibited low response to the peptide after booster immunization; however, the
response to the booster immunization in the control groups was inconsistent
causing the study to be inconclusive. While these studies do not present a final
protocol to modulate epitope-specific antibody responses, these results in
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combination with an examination of the existing literature can direct future
experimentation.
Future experimentation should evaluate alternative dosages of doxorubicin
for immunomodulation. In this study, we utilized a single injection of liposomal
doxorubicin which contained 160 µg of doxorubicin, a dosage of approximately 8
mg/kg in the experimental mice. While this dose is lower than the maximum
tolerated dose for liposomal doxorubicin of approximately 60 mg/mL, this dosage
may induce the epitope-independent suppression effect observed in this study.251
Oja et al reported that increasing dosage of liposomal doxorubicin increased the
effect of epitope-specific and epitope-independent suppression of a novel immune
response.169 Specifically, at 8 mg/kg they report total epitope-specific suppression
but also find significant epitope-independent effects.169 It is possible that despite
our suppression and immunization events being separated by 14 days, this dosage
of liposomal doxorubicin is simply too high. When evaluating epitope-specific
suppression of a preexisting immune response, Ichikawa and colleagues utilized
a lower dose of liposomal doxorubicin, 20 µg per dose, but gave that dose 3 times
over 5 days.170 This strategy induced epitope-specific suppression of
approximately 50% for IgE in their model.170 Future studies of modulation of an
existing immune response should evaluate the effect of liposomal doxorubicin over
a range of dosages to determine the optimal dose with high epitope-specific
suppression and low epitope independent suppression.
An additional factor to explore related to dosage is the route of administration.
In our study, we utilized an intraperitoneal injection strategy unlike the intravenous
injections utilized in other studies. Flow cytometry analysis of the peritoneal cavity
after doxorubicin liposomal administration indicates changes in cell populations
after administration of doxorubicin liposomes, specifically a trend towards
decreased percentage of cells which were CD19+ and F4/80high. Additionally, a
distinct population of unknown cells is visible in a forward and side scatter plot in
mice treated with liposomal doxorubicin. These local changes are particularly
important in this model because the FSL-A immunization is given intraperitoneally
so any non-specific local changes resulting from doxorubicin dosage may lead to
epitope-independent modulation of the immune response to FSL-A. Therefore,
further studies in a similar model could administer doxorubicin via intravenous
infusion and evaluate if epitope-independent effects are reduced.
Any future flow cytometry of the peritoneal cavity should use an optimized
antibody panel. In this study we utilize F4/80 as the monocyte and macrophage
marker; however, this marker has variable levels of expression on macrophages
in the peritoneal cavity and is potentially low in many monocytes and macrophages
in the peritoneal cavity after inflammation.252 Based on this, additional macrophage
markers such as Ly6C, CD11b and MHC-II should be included in future studies to
develop a full understanding of these cells in the peritoneal cavity.252 Further
84

examination of peritoneal lavage flow cytometry may also be needed regarding the
percentage of B cells. In our report, we detect approximately 70% of all cells as
CD19+ in naïve mice while other reports indicate the percentage of B cells in the
peritoneal cavity may be closer to 50% to 60%. However, these evaluations of B
cells in the peritoneal cavity differ in multiple ways such as mouse strain utilized,
the cell collection method and the detection antigen utilized.250, 253 Additionally, our
strategy to label epitope-specific B cells with a fluorescently labeled liposome failed
in this study. An alternative strategy would be to label B cells in vivo prior to
collection of cells, similar to the work by Ichikawa and colleagues.170 In their study,
they found co-localization of fluorescent ovalbumin liposomes and B cells in the
spleen of immunized mice. In future experiments, we could employ a similar
strategy by injecting fluorescently labeled liposomes prior to sacrifice and
analyzing cells via flow cytometry utilizing this marker.170
Use of an alternative peptide epitope may improve vaccination response. In
this study we utilized a peptide epitope derived from mouse ApoA-I protein which
has previously been utilized in our laboratory.186 While every mouse which
received liposomal doxorubicin labeled with the ApoA-I peptide had a low response
to the booster immunization, several mice in the control groups also had a poor
booster immunization response. The poor responders include mice which received
no liposomal doxorubicin. In contrast, in previous work from our laboratory using a
similar liposomal formulation induces a strong antibody response to the booster
immunization. One potential explanation is that previous work utilized C57BL/6
mice while in this study we utilized Balb/c mice. Previously published reports have
identified these strains can respond differently to either an immunization or an
infection.254, 255 For future studies it may be important to utilize an antigen which is
optimized for the strain of mice utilized in the study.
In conclusion, while this study failed to identify a final procedure to utilize
doxorubicin liposomes for the suppression of a preexisting immune response, it
can inform the design of future experimentation.
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Figure 5.1. Effect of doxorubicin liposomes on anti-FSL-A IgG in FSL-A
immunized mice.
A. Timeline for mouse experiment. B. Dot plot of absorbance values resulting from
anti-FSL-A IgG ELISA completed with a 1:200 dilution of mouse serum. C. Dot plot
of anti-FSL-A IgG absorbance values at day 35. There are 3 mice in the
unimmunized group, and 5 mice per group in the immunized groups. Half-filled
circles in B and C represent values above the maximum absorbance and reported
as A450 = 4.0. Comparisons in C utilize ANOVA with Bonferroni’s multiple
comparison. *, p < 0.05.
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Figure 5.2. Effect of doxorubicin liposomes on cells in the peritoneal cavity.
Flow cytometry of cells collected form peritoneal lavage. A. Gating strategy to
identify CD19+ cells, as well as F4/80High cells. Displaying plots from unimmunized
untreated mouse. B. Histogram of CD19+ cells by staining with liposome labeled
with FSL-A and DiD. Displaying plot of immunized untreated mouse. C. Dot plot of
percentage of CD19+ which were FSL-A+. D. Plot of forward and side scatter of
singlets to identify New Population in doxorubicin treated mice. Displaying plot
from immunized untreated mouse, and immunized and control-doxorubicin treated
mouse. E. Dot plot of percentage of singlets which were within the New Population.
F. Dot plot of percentage of New Population in doxorubicin treated mice which are
CD19+ or F4/80High. G and H. Dot plot of CD19+ cells and F4/80High cells as a
percentage of singlets. Legend from C is consistent throughout the dot plots.
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Figure 5.3. Effect of doxorubicin liposomes on mice immunized with both FSL-A
and ApoA-I141-184.

A – B. Dot plot of absorbance values resulting from (A) anti-FSL-A IgG ELISA or
(B) anti-ApoA-I141-184 IgG ELISA completed with a 1:200 dilution of mouse serum.
C - D. Dot plot of (C) anti-FSL-A IgG absorbance values or (D) anti-ApoA-I141-184

IgG absorbance values at day 35. Half filled symbols in represent values above
the maximum absorbance and reported as A450 = 4.0. Comparisons in C and D
utilize Kruskal-Wallis with Dunn’s multiple comparison, **, p < 0.01 and *, p < 0.05.
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CHAPTER 6. DISCUSSION AND FUTURE DIRECTIONS
The major focus of my work presented in this dissertation was the evaluation
of a potential risk factor for cardiovascular disease (CVD) events in patients.
During these evaluations, we developed an assay whose results independently
associated with CVD outcomes in patients with a history of coronary artery disease
(CAD), then identified and characterized the novel biomarker measured in this
assay.
An evaluation of the literature on CVD and immunobiomarkers lead to the
development of an ELISA to measure ApoA-I/IgG immune complexes (ICs) as a
potential risk factor for CVD development in patients. CVD is the largest cause of
morbidity and mortality both in the United States and around the world.1, 3 As
discussed in Chapter 1, many components of the immune system contribute to the
development of CVD, including B cells which produce highly specific antibodies.
The relative levels of these antigen-specific antibodies have subsequently been
investigated in patients leading to the identification of anti-ApoA-I IgG as a potential
biomarker for CVD events.111, 121 While many studies of anti-ApoA-I IgG find an
association between the level of these antibodies and CVD events,112-116 this
relationship is not fully robust as modification of the outcome measure or the
thresholds used to group subjects eliminate the significant association between
the antibody and CVD events.121 We sought to investigate an alternative form of
anti-ApoA-I IgG, IgG which is bound to ApoA-I in circulation as an IC. Several
publications support the existence of this biomarker, including reports of ApoAI/IgG ICs in blood collected from mice and humans; however, there was no
evaluation of this IC in the context of CVD events.146, 147, 198-200 The ELISA we
developed to quantify ApoA-I/IgG ICs was constructed in a similar manner as an
ELISA to measure ApoB ICs,108 in this case we utilized a capture antibody derived
from goats which was specific for ApoA-I and a detection antibody targeting human
IgG. The goal of this design was to detect any IgG bound to ApoA-I in circulation.
6.1

Major results

Decreased concentrations of the analyte detected by ELISA are associated
with increased adverse events in patients with a history of CAD. As discussed in
chapter 2, we utilized this ELISA in several patient populations, including a well
characterized cohort of patients with a history of CAD. Evaluation of this ELISA in
patients with CAD found that 93% of this population had levels statistically elevated
above background. Additionally, these patients were followed for a median of 4.1
years after cardiac catheterization. Evaluation of the occurrence of either all-cause
mortality, non-fatal myocardial infarction, or non-fatal stroke during this period
indicates that patients in the lowest tertile for this biomarker experienced increased
events as compared to patients in the highest tertile. This result was still significant
after adjustment for common cardiovascular risk factors. The association of these
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ELISA results with CVD events in patients prompted further study of this biomarker
in our laboratory.
Subclass characterization of the antibodies in this analyte indicate an antiinflammatory state. The association of this biomarker with future CVD events
prompted evaluation of the IgG subclasses which contribute to the analyte.
Analysis of IgG subclasses in plasma indicates a trend towards enrichment of the
anti-inflammatory IgG4 within the total IgG composition of subjects with elevated
responses in our assay. Further, evaluation of the IgG1 to IgG4 ratio indicates
relative enrichment of anti-inflammatory IgG4 within the analyte as compared to
total plasma.
Evaluation of the ELISA indicates the presence of assay interferents. Due to
multiple failures in attempts to isolate the analyte from total IgG, we sought to verify
the identity of the biomarker. For this purpose, we tested this ELISA with three
distinct capture antibodies, as this change should alter the specificity of the assay.
Unexpectedly, the results with these distinct goat capture antibodies were similar,
an indication that the biomarker measured was not ApoA-I/IgG ICs but an
interfering antibody binding to goat IgG.
Further evaluation confirms that the assay measures human IgG anti-goat
IgG (HAGA). In chapter three, we initially confirmed that absorbance values in this
ELISA were similar despite the use of three distinct goat capture antibodies in a
larger population of blood donors. In further evaluation with competition ELISAs,
we found that binding to goat IgG could be inhibited by addition of IgG from goats,
cows and sheep, all members of the phylogenetically related Bovidae family, but
not the addition of IgG from rabbits or mice. We also utilized protein G affinity to
isolate total IgG from plasma, confirming that the factor binding to goat IgG in these
assays is a human IgG.
Additional characterization experiments indicate that HAGA binds with high
affinity to the heavy chain of goat IgG via unknown epitopes. Western blotting of
denatured goat IgG indicates that binding is directed to the heavy chain of goat
IgG. However, further experimentation via deglycosylation or peptide array failed
to identify a specific epitope. Preliminary binding characterization studies confirm
binding of human IgG to two distinct goat IgG capture antibodies and find that this
binding is a high affinity interaction despite the use of crude IgG, not epitope
purified IgG.
Our laboratory has the ability to measure SARS-CoV-2 serology via highthroughput screening. In response to the SARS-CoV-2 pandemic our laboratory
successfully modified an established ELISA protocol to utilize reagents already
present for the measurement of anti-SARS-CoV-2 antibodies. Subsequently, our
laboratory was able to utilize these procedures with an automated plate washing
and dispensing system with a stack of up to 30 plates at a time. Additionally, our
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preliminary validation studies indicate that our procedure can identify previously
infected patients via seropositivity when using three different antigens.
Further optimization is needed to establish a epitope-specific doxorubicin
suppression strategy. Our evaluation of epitope-specific suppression with
doxorubicin liposomes indicates that injection of these liposomes into the
peritoneal cavity caused non-epitope-specific suppression of a carbohydrate
antigen, which is immunized intraperitoneally. Further analysis via flow cytometry
suggests that this occurs due to the local changes of peritoneal cells after injection
of doxorubicin liposomes. While evaluation of epitope-specific suppression with
peptide-conjugated doxorubicin liposomes was pursued, the results were mixed
due to the variable response to re-immunization in the control mice. Importantly
the mice that received suppression liposomes exhibited reduced antibody
responses to re-immunization, providing a trend towards successful suppression.
6.2

Significance and Conclusions

The association between CVD events and HAGA expands the potential role
of interfering antibodies in patient samples. Previous reports have established the
presence of human antibodies which bind to animal antibodies in immunoassays,
but the evaluation of these antibodies generally centers on their impact in the
clinical assays which drive patient care.208, 212 While in terms of our original assay
design HAGA is an assay interferent, causing false positives in the ApoA-I/IgG IC
ELISA, our work indicates that it is also a potential biomarker, as the level of this
interfering antibody is associated with future CVD events in patients with CAD.
This extended evaluation of an interfering antibody is, to our knowledge, the first
report of an association between an interfering antibody and CVD outcomes in
patients.
Characterization of HAGA may provide an indication of the origin of HAGA in
patients. In an influential review Levinson and Miller divide interfering antibodies
into classes of either natural heterophilic antibodies or induced human anti-animal
antibodies (HAAA), specifically, they postulate that heterophilic antibodies show
broad specificity and weak binding while HAAA bind tightly and specifically.141 The
results of our competition ELISA show that HAGA is specific for antibodies from
the Bovidae family, as interference is low when using either rabbit or mouse IgG.224
Additionally, preliminary binding data indicate that HAGA binds with high affinity.
These results suggest that we are measuring a specific and high affinity response,
which based on the Levinson and Miller model is the result of an immunization
event.
The immunization event leading to HAGA in patients is potentially the
exposure to IgG in cow’s milk. In our assay we utilize a goat antibody as the coating
antigen; however, the competition experiments indicate that HAGA binding is
impacted similarly by goat, cow and sheep IgGs, all similar proteins from the
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Bovidae family.224 This cross reactivity is a potential indication that the immunizing
event potentially is not exposure to goat IgG but instead the exposure to cow or
sheep IgG. Critically, antibodies targeting proteins found within cow’s milk are
known to be present in patients beyond early childhood.217 While evaluation of anticow’s milk antibodies does not include IgG as an antigen, cow IgG is known to be
present in cow’s milk.217, 218 This hypothesis for the origin of HAGA in patients is
as of yet untested, and further evaluation is necessary prior to making a definitive
conclusion.
Evaluation of the antibody response to SARS-CoV-2 in patients may enable
a further understanding of the pandemic. A potential issue with understanding the
rates of infection throughout the pandemic is that PCR positivity is reduced after
the initial infection, an indication that this gold standard test for diagnosis is not a
measure of prior infection.233 However, previous work using similar serological
assays to those optimized in our laboratory, as well as preliminary validation data
presented in chapter 4, shows an ability to identify patients previously infected
SARS-CoV-2 in comparison to control samples.155, 156 This identification may prove
vital as serological evaluations indicate that the infection rate during the initial
surge of SARS-CoV-2 may have been 10 times that identified via PCR positivity
and that patients with SARS-CoV-2 seropositivity have a decreased risk of new
SARS-CoV-2 infection in comparison to seronegative subjects.157-161 Further, as
new strains of the virus develop due to mutation, specific serological assays can
potentially indicate if patients have antibodies which bind to the modified
proteins.256 While these screening assays can provide an initial indication of the
effect, complementary work including neutralizing antibody assays and T cell
activation assays may prove necessary to fully characterize the effect of variant
viruses on the immune response.
Development of epitope-specific suppression to pathophysiologically
relevant antigens may lead to a novel therapeutic strategy. Previous work with
doxorubicin liposomes has focused on establishing the potential of the liposomes
to alter the immune response specifically, either blocking the establishment of an
initial response or altering the level of IgE developed after re-immunization.169, 170
This critical initial work has focused on using the model antigen ovalbumin for
study; however, further studies evaluating the efficacy of this strategy will
necessitate use of antigens with a greater relevance to human health. In chapter
5, we seek to use both the blood group A antigen carbohydrate, and a peptide from
the mouse ApoA-I protein, as clinically relevant epitopes associated with adverse
transfusion reactions, and poor CVD outcomes, respectively.112-116, 120, 121, 257 While
the evaluations present in chapter 5 do not establish an optimized protocol for
epitope-specific suppression, further work should continue to focus on
physiologically relevant antigens, similar to the success of the Payne group which
is evaluating the use of epitope-specific suppression with CAR-T cells by using a
model of the autoimmune disease Pemphigus Vulgaris.248, 249
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6.3

Future Studies

The results and conclusions presented in this dissertation prompt further
evaluation of HAGA and related biomarkers. These further experiments studying
HAGA should include an evaluation of the predictive role of HAGA in patients
without a history of CVD events, as well as an evaluation of the origin of HAGA,
identification of epitopes targeted by HAGA and assessment of any direct
mechanistic link between HAGA and CVD progression. Additionally, in chapter 3
we identify IgG antibodies from patients which bind to rabbit anti-RFP IgG, further
experiments should explore this antibody response.
Evaluation of HAGA in patients without preexisting CVD can further the
association of this biomarker with CVD events. In chapter 2, we found an
association between a biomarker determined to be HAGA and CVD events in
patients with a history of CAD. Importantly, these patients are at an elevated risk
of CVD events due to their clinical history and may not represent a general
population.258 Therefore, HAGA should be measured in an asymptomatic patient
population for the prediction of initial CVD events. The ideal cohort to investigate
for HAGA-based predictive modeling is the Multi-Ethnic Study of Atherosclerosis
(MESA), a multi-center population-based prospective study of subjects without
pre-existing CVD.259 The cohort include over 6800 subjects at baseline with over
14 years of follow-up data and up to four additional blood draws. Importantly, these
samples are associated with detailed medical and social histories, demographic
data and a compilation of data collected from the more than of 1800 publications
based on this cohort. To enable measurement of this large cohort of patients, the
HAGA assay was adapted for use on the automated microplate washing and
dispensing system in chapter 2 which facilitate the measurement of 400 samples
at a time. Additionally, in chapter 4 we observe low variability over a set of 30
microplates when completing serology ELISAs which utilize incubations at room
temperature. Evaluation of the HAGA ELISA with similar conditions may enable
more rapid evaluation of samples, up to 1200 samples at a time.
Given the association between HAGA and CVD events, determination of the
origin of HAGA in patients is warranted. Our characterization of HAGA indicates
that they may develop after an immunization event and we hypothesize this event
may be exposure to IgG within cow’s milk. Several strategies may provide clarity
in the plausibility of this model. For evaluation in animal models, a potential
strategy is to specifically expose animals to cross-species milk and follow the
development of an immune response targeting foreign antibodies over time. A
strategy utilizing preexisting clinical samples would be evaluation of both HAGA
and anti-cow’s milk antibodies in a patient population to determine if these antibody
responses are highly correlated. This experiment would be similar to one
conducted in the early identification of interfering antibodies as Ammann and Hong
noted that interfering antibodies were common in patients with both IgA deficiency
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and anti-cow’s milk antibodies.136 Alternatively, a clinical trial could be designed
based a history of exposure to cow’s milk, similar to the structure of the trial by
Keller et al.215 Infants exclusively fed breast milk would be recruited into the trial
and assayed for pre-existing HAGA and human anti-cow IgG (HACA). Following
initial exposures to cow’s milk, subjects would be followed to monitor the
development of HAGA and HACA over time. The results of these studies would
provide an indication of the connection between exposure to cow’s milk and HAGA
development.
Identification of epitopes targeted by HAGA may facilitate further
experimentation. After our determination that this biomarker was HAGA, we sought
to identify the targeted epitopes as described in chapter three. Western blot
analysis indicated that binding is directed to the heavy chain of goat IgG. Based
on this, we attempted to identify more specific epitopes by deglycosylating the
antibody and evaluating peptides identified in a microarray; however, neither
strategy identified specific epitopes. Further work seeking to identify peptide
epitopes can begin by re-analyzing the microarray beyond the 4 peptides we
selected. Specifically, there are areas of potential binding in the hinge region of
IgG1 and 2 as well as a region within the CH3 domain of all three antibody
subclasses. These peptides can be evaluated in a similar manner to the
experiments completed with the original peptides, including competition and direct
binding studies. Expanding beyond this current peptide array, evaluation of
epitopes is possible by shotgun mutagen analysis, a process where antibodies are
tested against a library of proteins which each contain directed mutations allowing
for identification of mutations which decrease binding.260 Any epitopes identified
via this method would need subsequent analysis to verify the target. If a target is
validated it should be analyzed for homology, with a specific evaluation for proteins
from pathogens. This evaluation can indicate if HAGA potentially develops as a
result of molecular mimicry, a process where an antibody response initially target
a pathogen, but cross-react after affinity maturation.261 An additional advantage of
epitope identification is that many strategies to isolate epitope-specific antibodies
are developed using peptide antigens, therefore, isolation of HAGA may be eased
if the binding epitope is determined.262, 263
If continued experimentation finds associations between HAGA and CVD
events, these results will prompt evaluation of a mechanistic link between HAGA
and atherosclerosis. Completion of mechanistic experiments necessitates the
isolation of HAGA from the rest of plasma, a process which will be potentially eased
by the identification of specific peptide epitopes. Once these antibodies are
purified, they can be utilized in testing both in vitro and in vivo. Based on our finding
that HAGA are enriched in IgG4, evaluation of the effect of these antibodies on
inflammation is warranted. Previous reports find that IgG4 ICs shift macrophage
polarization and induce the expression of IL-10, an anti-inflammatory cytokine.257,
264
Such experiments can be repeated with HAGA, and particularly HAGA which is
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mixed with goat IgG prior to addition to cells. HAGA can also be tested in vivo,
potentially to evaluate interactions between HAGA with ingested IgG. For this
purpose, mice can be passively immunized with HAGA, which has been
conjugated for later purification, and given either milk or IgG orally. After sacrifice
and purification of HAGA, the level of bound IgG can be quantified to assess the
interactions in vivo between HAGA and ingested IgG. This assessment will
potentially reveal if cow IgG, or peptides from digested cow IgG, are exposed to
HAGA in vivo. If these interactions are detected, future experiments can evaluate
how this antibody-antigen interaction impacts inflammation both locally in the GI
track and systemically. Importantly, evaluation of HAGA in the MESA cohort may
provide alternative potential mechanisms, particularly if HAGA is found to correlate
with a specific biomarker, risk factor or clinical characteristic. If this is the case, the
potential mechanistic experiments needed would shift based on this new
information.
As we identified HAGA in patients, we also observed human antibodies
binding to rabbit IgG, a potential indication of human IgG targeting anti-rabbit IgG
(HARA). In our experiments confirming the effect of capture antibody on
absorbance values in chapter 3, we utilized a rabbit antibody targeting red
fluorescent protein (RFP) as an alternative capture antibody. While the focus of
our work was on the characterization of HAGA, we observed that patients possess
antibodies targeting the rabbit IgG. In the subsequent competition ELISAs, we
demonstrate that HAGA did not bind to rabbit IgG, an indication that the antibodies
binding to rabbit IgG are a separate antibody response. This identification of a
separate anti-animal antibody response in the same patients encourages
characterization of HARA similar to the experiments completed to characterize
HAGA in chapter 3. Additionally, based on the association of CVD events and
HAGA, evaluation of HARA in a pilot population of patients is warranted to
determine if there is any association with CVD or clinical characteristics. If
characterization of HARA reveals similar properties to that of HAGA, epitope
identification experiments should be completed to compare the peptide targets of
these antibodies to determine if they arise from a common cause. Characterization
of an additional form of HAAA will provide greater context for these understudied
antibody responses.
Our laboratory has the ability to contribute public health efforts via SARSCoV-2 serology testing. A primary goal in the development of anti-SARS-CoV-2
assay testing was to identify subjects previously infected with the virus and who
were likely resistant to re-infection. Given the capacity of our laboratory to test up
to 1200 subjects per day we are well equipped to contribute to continued efforts to
identify seropositive subjects. Additionally, population screening has been utilized
to better understand the true rate of SARS-CoV-2 infection, beyond the rate
determined via PCR testing of active cases.157 Given the relationship of the
College of Pharmacy with healthcare providers in local communities, our laboratory
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has the potential to evaluate the rate of infection in potentially underserved
areas.239 Further, our initial validation experiments indicate that we can detect
seropositivity to three antigens, the Spike, the RBD region, and the N protein, given
that vaccinations focus on the Spike and RBD antigens, our laboratory can
potentially differentiate between vaccinated subjects and subjects with previous
infections by comparing the responses to the N protein and either RBD or spike
proteins.240-243 This enables a finer evaluation of the cause of seropositivity which
may prove vital based on the relative immunoprotection provided by either
vaccination or a history of infection on the newly endemic variant forms of SARSCoV-2.
The protocol for epitope-specific immunosuppression with doxorubicin
liposomes requires continued optimization. While the results in chapter 5 suggest
the potential of doxorubicin liposomes to reduce epitope specific immune
responses, these data are limited by experimental design which must be modified
in subsequent studies to explore this hypothesis. One major complication identified
in our studies is the local effect of doxorubicin liposomes when injected
intraperitoneally rsulting in non-specific immune suppression toward FSL-A and
alterations in the intraperitoneal cell populations as determined via flow cytometry.
To avoid this complication, liposomal doxorubicin can be introduced via an
alternative route, such as intravenous injection as used in some previously
published work, particularly when studying an intraperitoneally immunized
antigen.169, 170 A further area in need of optimization is the use of an antigen which
is both physiologically relevant, and will induce a consistently strong
reimmunization immune response. In chapter 5 we utilized an antigen from ApoAI which we had previously found to induce a strong immunization response in
C57Bl/6 mice; however, in this study with Balb/c mice the reimmunization response
was weak and inconsistent.186 This is potentially a result of differential immune
responses between mouse strains.254, 255 Therefore, in future studies it will be
necessary to establish the immunogenicity of the antigen in the strain of mice used
in the study.
In conclusion, the work within this dissertation demonstrates the utility of
strategies to modulate epitope specific immune responses, and the development
of assays to measure immune responses in patients. These assays provide a
platform to monitor seroprevalence, as demonstrated with SARS-CoV-2, while
also serving as a mechanism to improve clinical diagnoses. The majority of the
work presented in this dissertation describes the use of ELISA to quantify the
presence of HAGA within human subjects and the association of HAGA with CVD
events in a specific patient population. These results prompt continued exploration
of HAGA, and the potentially related biomarker HARA, to confirm any association
with CVD events and to understand the development and mechanistic role of these
antibodies in CVD.
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